US20140080767A1 - Maternal sialic acid supplementation - Google Patents
Maternal sialic acid supplementation Download PDFInfo
- Publication number
- US20140080767A1 US20140080767A1 US14/084,986 US201314084986A US2014080767A1 US 20140080767 A1 US20140080767 A1 US 20140080767A1 US 201314084986 A US201314084986 A US 201314084986A US 2014080767 A1 US2014080767 A1 US 2014080767A1
- Authority
- US
- United States
- Prior art keywords
- sialic acid
- day
- female
- acid
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title claims abstract description 353
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title claims abstract description 247
- 230000009469 supplementation Effects 0.000 title abstract description 76
- 230000008774 maternal effect Effects 0.000 title description 55
- 230000035935 pregnancy Effects 0.000 claims abstract description 78
- 210000003754 fetus Anatomy 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 35
- 238000011161 development Methods 0.000 claims abstract description 29
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 78
- 102000047918 Myelin Basic Human genes 0.000 claims description 75
- 101710107068 Myelin basic protein Proteins 0.000 claims description 75
- 239000002552 dosage form Substances 0.000 claims description 60
- 230000006651 lactation Effects 0.000 claims description 47
- 210000004556 brain Anatomy 0.000 claims description 45
- 230000001965 increasing effect Effects 0.000 claims description 43
- 230000008901 benefit Effects 0.000 claims description 31
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 claims description 24
- 210000002241 neurite Anatomy 0.000 claims description 23
- 235000013305 food Nutrition 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 235000015872 dietary supplement Nutrition 0.000 claims description 12
- 210000004885 white matter Anatomy 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 10
- CERZMXAJYMMUDR-QBTAGHCHSA-N 5-amino-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid Chemical compound N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO CERZMXAJYMMUDR-QBTAGHCHSA-N 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- 102000006386 Myelin Proteins Human genes 0.000 claims description 6
- 108010083674 Myelin Proteins Proteins 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 150000002270 gangliosides Chemical class 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 235000001055 magnesium Nutrition 0.000 claims description 6
- 229940091250 magnesium supplement Drugs 0.000 claims description 6
- 210000005012 myelin Anatomy 0.000 claims description 6
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 6
- OVRNDRQMDRJTHS-OZRXBMAMSA-N N-acetyl-beta-D-mannosamine Chemical compound CC(=O)N[C@@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-OZRXBMAMSA-N 0.000 claims description 5
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 claims description 5
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 claims description 5
- 108010067454 caseinomacropeptide Proteins 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 229940108928 copper Drugs 0.000 claims description 4
- RTEOJYOKWPEKKN-TVCQNHEDSA-N n-[(3s,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]propanamide Chemical compound CCC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O RTEOJYOKWPEKKN-TVCQNHEDSA-N 0.000 claims description 4
- 210000000653 nervous system Anatomy 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 claims description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 3
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 claims description 3
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 3
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 3
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 3
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229930003448 Vitamin K Natural products 0.000 claims description 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 3
- 241000234314 Zingiber Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 3
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- 239000011795 alpha-carotene Substances 0.000 claims description 3
- 235000003903 alpha-carotene Nutrition 0.000 claims description 3
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 claims description 3
- 235000013734 beta-carotene Nutrition 0.000 claims description 3
- 239000011648 beta-carotene Substances 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 235000002360 beta-cryptoxanthin Nutrition 0.000 claims description 3
- 239000011774 beta-cryptoxanthin Substances 0.000 claims description 3
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229960005069 calcium Drugs 0.000 claims description 3
- 235000001465 calcium Nutrition 0.000 claims description 3
- 229960001231 choline Drugs 0.000 claims description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 239000011663 gamma-carotene Substances 0.000 claims description 3
- 235000000633 gamma-carotene Nutrition 0.000 claims description 3
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- 210000004884 grey matter Anatomy 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 229960003284 iron Drugs 0.000 claims description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 3
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 3
- 235000008696 isoflavones Nutrition 0.000 claims description 3
- 235000012680 lutein Nutrition 0.000 claims description 3
- 239000001656 lutein Substances 0.000 claims description 3
- 229960005375 lutein Drugs 0.000 claims description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 3
- 235000012661 lycopene Nutrition 0.000 claims description 3
- 239000001751 lycopene Substances 0.000 claims description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 3
- 229960004999 lycopene Drugs 0.000 claims description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 3
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 3
- 230000037420 neurological improvement Effects 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 235000014786 phosphorus Nutrition 0.000 claims description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 3
- 235000013406 prebiotics Nutrition 0.000 claims description 3
- 239000006041 probiotic Substances 0.000 claims description 3
- 235000018291 probiotics Nutrition 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 235000011649 selenium Nutrition 0.000 claims description 3
- 235000019157 thiamine Nutrition 0.000 claims description 3
- 239000011721 thiamine Substances 0.000 claims description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- 229930003802 tocotrienol Natural products 0.000 claims description 3
- 239000011731 tocotrienol Substances 0.000 claims description 3
- 235000019148 tocotrienols Nutrition 0.000 claims description 3
- 229940068778 tocotrienols Drugs 0.000 claims description 3
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 235000019168 vitamin K Nutrition 0.000 claims description 3
- 239000011712 vitamin K Substances 0.000 claims description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- 229940046010 vitamin k Drugs 0.000 claims description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 3
- 235000010930 zeaxanthin Nutrition 0.000 claims description 3
- 239000001775 zeaxanthin Substances 0.000 claims description 3
- 229940043269 zeaxanthin Drugs 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 235000016804 zinc Nutrition 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- 229930003270 Vitamin B Natural products 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 10
- 230000036541 health Effects 0.000 abstract description 8
- 239000013589 supplement Substances 0.000 abstract description 6
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000001605 fetal effect Effects 0.000 abstract description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 108
- 210000000877 corpus callosum Anatomy 0.000 description 43
- 230000018109 developmental process Effects 0.000 description 24
- 235000005911 diet Nutrition 0.000 description 22
- 230000037213 diet Effects 0.000 description 22
- FDJKUWYYUZCUJX-AJKRCSPLSA-N N-glycoloyl-beta-neuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-AJKRCSPLSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 230000004641 brain development Effects 0.000 description 14
- 230000012010 growth Effects 0.000 description 13
- 235000020256 human milk Nutrition 0.000 description 13
- 210000004251 human milk Anatomy 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 11
- 210000002475 olfactory pathway Anatomy 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 230000001953 sensory effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000001638 cerebellum Anatomy 0.000 description 8
- 230000000971 hippocampal effect Effects 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 7
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 210000001320 hippocampus Anatomy 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 235000013350 formula milk Nutrition 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- CLRLHXKNIYJWAW-UHFFFAOYSA-N KDN Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1O CLRLHXKNIYJWAW-UHFFFAOYSA-N 0.000 description 4
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 description 4
- 238000003365 immunocytochemistry Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 229930186217 Glycolipid Natural products 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 3
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- -1 carbon amino sugar Chemical class 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000000009 lactational effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 235000021416 maternal diet Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000013135 GNE myopathy Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002804 pyramidal tract Anatomy 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 description 1
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-ZTVVOAFPSA-N N-acetyl-D-mannosamine Chemical compound CC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-ZTVVOAFPSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 241001479489 Peponocephala electra Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 229950003073 aceneuramic acid Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000008133 cognitive development Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002594 corticospinal effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 108091008710 cutaneous receptors Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940059082 douche Drugs 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001263 extrapyramidal tract Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009554 growth spurt Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000027984 hippocampus development Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011670 long-evans rat Methods 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108091008706 proprioceptors Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Definitions
- the invention relates to supplements containing sialic acid and the use of such supplements for a female that can result in developmental benefits for a fetus and/or child.
- LCPUFAs long-chain polyunsaturated fatty acids
- DHA docosahexaenoic acid
- LCPUFAs long-chain polyunsaturated fatty acids
- DHA docosahexaenoic acid
- other components of human milk might be important to brain growth and development of a fetus or child.
- enzymes, hormones, growth factors, and sialic acid are found in human milk and are typically poorly represented in infant formulas. See, e.g., McVeagh and Miller, J. Paediatr. Child Health 1997; 33:281-286.
- sialic acid has been shown to have a simultaneous presence in significant amounts in both human milk and human brain. See, e.g., McVeagh and Miller, J. Paediatr. Child Health 1997; 33:281-286.
- Sialic acid is a generic term for the N- or O-substituted derivatives of neuraminic acid, a monosaccharide with a nine-carbon backbone, that are a structural and functional component of gangliosides. See, e.g., Varki and Schauer (2009) in Essentials of Glycobiology. 2 nd ed., Cold Spring Harbor Press. Ch. 14; and FIG. 1 .
- the most predominant sialic acid found in mammals is N-acetylneuraminic acid (NANA).
- sialic acid inactivation of the gene encoding an enzyme of sialic acid biosynthesis, uridine diphospho-N-acetylglucosamine (UDP-GlcNAc) 2-epimerase/N-acetylmannosamine (MacNAc) kinase (GNE/MNK), has been correlated with reduced sialic acid levels and the development of hereditary inclusion body myopathy (HIBM), an adult-onset progressive neuromuscular disorder.
- HIBM hereditary inclusion body myopathy
- a mother's increased intake of some nutrients can benefit her child's brain development.
- some nutrients e.g., docosahexaenoic acid
- maternal supplementation with sialic acid clearly resulted in developmental benefits for a fetus or child, suggesting that maternal supplementation with sialic acid is needed.
- the present invention addresses this need by providing sialic acid which can be administered to a female during preconception, pregnancy/gestation and/or lactation/postpartum as described herein.
- the most rapid rate of brain development (“the brain growth spurt”) occurs during gestation and extends to at least the end of the first year of life.
- the present invention optimizes the developmental benefits of maternal supplements such as sialic acid for a fetus or child by providing supplementation during this critical period of brain development.
- the present invention is directed to compositions and methods for providing sialic acid to a female, comprising the administration of sialic acid to the female during at least one of the stages of preconception, pregnancy and lactation.
- the sialic acid provides a developmental benefit to a fetus or child of the female.
- the sialic acid is a free sialic acid.
- the sialic acid is selected from the group consisting of: oligosaccharide conjugates, lipid conjugates, protein conjugates, and combinations thereof.
- the sialic acid is selected from the group consisting of: 3 ′sialyllactose, gangliosides, and casein glycomacropeptide.
- the sialic acid is in the form of n-acetylneuraminic acid.
- the sialic acid is a sialic acid precursor that is metabolized into sialic acid.
- the sialic acid precursor is selected from the group consisting of: N-acetylmannosamine, N-propanoylmannosamine, 2-keto-3-deoxynononic acid, N-glycolylneuraminic acid, and the core sialic acid neuraminic acid molecule.
- the sialic acid is administered during pregnancy and lactation. In some embodiments, the sialic acid is administered during preconception, pregnancy and lactation. In some embodiments, the sialic acid is administered during about the first two years following birth.
- the developmental benefit is improved nervous system growth and/or development or growth of the brain of the fetus or child. In some embodiments, the developmental benefit is a neurological improvement of the brain. In some embodiments, the developmental benefit is selected from the group consisting of: increased expression and/or development of mature myelin, enhanced neurite extension, increased levels of myelin basic protein, and enhanced development the white matter of the brain. In some embodiments, the developmental benefit is in the gray matter of the brain.
- the sialic acid is administered to the female in a dosage form.
- the dosage form is selected from the group consisting of: nutritional supplements, foods, pharmaceutical formulations, beverages and combinations thereof.
- the dosage form contains sialic acid at an amount of 0.01% to 10% by weight of the dosage form. In some embodiments, the dosage form contains sialic acid at an amount of 10% to 90% by weight of the dosage form.
- the sialic acid is administered to the female at an amount of 5 mg/kg/day to 200 mg/kg/day of the female's body weight. In some embodiments, the sialic acid is administered at an amount of 25 mg/kg/day to 100 mg/kg/day of the female's body weight. In some embodiments, the sialic acid is administered at an amount of 20 mg/day to 4000 mg/day. In some embodiments, the sialic acid is administered at an amount of 200 mg/day to 2000 mg/day.
- the methods further comprise administering the sialic acid to the female in a dosage form comprising sialic acid and an excipient.
- An excipient can be, for example, one or more of polyunsaturated fatty acids, calcium, folic acid, vitamin E, tocotrienols, vitamin D, magnesium, phosphorus, vitamin K, iron, vitamin B12, niacin, thiamine, riboflavin, biotin, vitamin B6, and isoflavones, zinc, pantothenic acid, medium chain triglycerides, copper, manganese, magnesium, vitamin A, choline, vitamin C, iodine, selenium, prebiotics, probiotics, beta-carotene, lutein, lycopene, alpha-carotene, zeaxanthin, beta-cryptoxanthin, gamma carotene, ginger, and tryptophan.
- FIG. 1 is a schematic depicting members of the sialic acid family.
- FIGS. 2 and 3 A- 3 B show the dietary regimens of rats receiving sialic acid-supplemented diets, the effects of which are described in the Examples.
- FIGS. 4A-4B show the effects of maternal sialic acid supplementation on the expression of myelin basic protein (MBP), normalized to ⁇ -actin expression, in the brains of the developing offspring (rat).
- MBP myelin basic protein
- FIGS. 5A-5C and 6 A- 6 B show the effects of maternal sialic acid supplementation on neurite extension in cultures of hippocampal cells derived from the offspring.
- FIGS. 7A-7C , 8 A- 8 D, 9 A- 9 B, 10 A- 10 D, 11 A- 11 B and 12 A- 12 B show the effects of sialic acid supplementation on the thickness ( FIGS. 7-11 ) or levels ( FIG. 12 ) of MBP expression in specific regions of the developing rat brain.
- FIGS. 13A-13B show NANA and Neu5Gc concentrations in cerebrospinal fluid (CSF) following NANA administration.
- the present invention provides methods and compositions for improving female, fetal and/or child health and development through nutritional supplementation with, for example, sialic acid.
- sialic acid can be administered to a female before, during and/or after pregnancy to improve the health and development of a fetus and/or child, including the developmental benefits described further herein.
- the sialic acid can be in a variety of forms in the supplements, including the dosage foams described further herein.
- a “child” of the present invention includes, but is not limited to, an individual or subject of any sex that is of an age between the time of delivery to approximately two years after delivery or to the time that breastfeeding has stopped, whichever is longer. This term includes infants and toddlers.
- a “female” of the present invention includes, but is not limited to, an individual or subject that is the biological mother of a fetus or child, a surrogate carrier of a fetus, and an individual or subject that breastfeeds a child. This term also includes an individual or subject that is attempting to become pregnant.
- a “maternal supplement” of the present invention can be administered to and useful for any female described herein.
- breastfeeding includes, but is not limited to, feeding from a female's breast (e.g., nursing) and feeding a child breast milk from a bottle (e.g., bottlefeeding). This includes a female who both breastfeeds and feeds infant formula to her child (e.g., partial breastfeeding).
- sialic acid refers to any member alone, or in combination with one or more other members, of the known family of derivatives of the nine-carbon sugar neuraminic acid. This term includes any sialic acid substitutions or variants and any precursors for sialic acid known in the art and described herein. This term includes conjugated and non-conjugated forms of sialic acid and free sialic acid. In some embodiments, the sialic acid is N-acetylneuraminic acid.
- sialic acid supplementation refers to administration of sialic acid to a female resulting in a developmental benefit for a fetus and/or child.
- a “precursor of sialic acid” or “sialic acid precursor” refers to a compound that is metabolized to faun sialic acid.
- a sialic acid precursor can include, but is not limited to, N-acetylmannosamine, N-propanoylmannosamine, 2-keto-3-deoxynononic add (KDN), N-glycolylneuraminic acid (Neu5Gc), the core sialic acid neuraminic acid molecule (Neu), and combinations thereof.
- a “developmental benefit” refers to an improvement in a factor related to the development or growth of a fetus or child.
- Developmental benefits of a fetus or child can include one or more of, but are not limited to, enhanced nervous system growth and/or development, neurological improvements, increased expression and/or development of mature myelin, increased neurite extension (e.g., in the hippocampus), increased levels of myelin basic protein (e.g., in the whole brain, cerebellum, corpus callosum, frontal and/or rostral corpus callosum, middle corpus callosum, midline corpus callosum decussation, lateral olfactory tract, motor output pathways, sensory input pathways, motor pyramids, and/or medial lemniscus), increased development of white matter (e.g., in the corpus callosum, lateral olfactory tract, or other white matter tracts as described above but not limited to the above), and enhanced hippocampal development, as described further here
- preconception refers to the period during which a female is attempting to become pregnant.
- administration of sialic acid during preconception is useful for the period of time from conception to when a female realizes she is pregnant or when a pregnancy is confirmed.
- pregnancy/gestation As used herein, the terms “pregnancy/gestation,” “pregnancy” and “gestation” refer to the period of time from conception to the delivery of a fetus.
- the stages of pregnancy/gestation include stage I (the first trimester), stage II (the second trimester) and stage III (third trimester).
- lactation/postpartum refers to the period of time from the delivery of a fetus to approximately two years after delivery or to the time that breastfeeding is stopped.
- Sialic acid includes a family of over 50 known derivatives of the nine-carbon sugar neuraminic acid (5-amino-3,5-dideoxy-D-glycero-D-galacto-nonulsonic acid). See, e.g., Schauer, Glycoconj. J. 2000; 17:485-499 and FIG. 1 . As an individual compound or moiety, sialic acid is a 9 carbon amino sugar, the structure of which is readily described in the chemical literature. See, e.g., Kontou et al., Biol. Chem. 2009; 390:575-579.
- N-acetylneuraminic acid is the most widespread form of sialic acid in humans. See, e.g., Kontou et al., Biol. Chem. 2009; 390:575-579.
- N-acetylneuraminic acid examples include sialic acid; O-Sialic acid; 5-Acetamido-3,5-dideoxy-D-glycero-D-galacto-2-nonulosonic acid; 5-Acetamido-3,5-dideoxy-D-glycero-D-galactonulosonic acid; Aceneuramic acid; N-acetyl-neuraminate; N-Acetylneuraminic acid; NANA; and Neu5Ac.
- Sialic acid molecules can be substituted in more than one position, with O-substitution occurring at C4, -7, -8 and -9 (O-acetyl, O-methyl, O-sulphate, and phosphate groups) and the introduction of a double bond between C-2 and C-3 can give rise to a wide variety of possible isomers. See, e.g., Kontou et al., Biol. Chem. 2009; 390:575-579 and FIG. 1 . Another modification is the presence of a hydroxyl group instead of an amino group at position 5 of the sugar, leading to 2-keto-3-deoxy-nonulosonic acid (KDN), which has been found in fish eggs and red blood cells. See, e.g., Kontou et al., Biol. Chem. 2009; 390:575-579 and Inoue et al., J. Biol. Chem. 1998; 273:27199-27204.
- KDN 2-keto-3-deoxy-nonulo
- any source of sialic acid can be used in the compositions and methods of the present invention, including, but not limited to, animal, plant and microbial sources.
- exemplary sources include, but are not limited to, sialic acid in monomeric or linked forms such as monomeric N-acetyl-neuraminic acid or polysialic acid; sialic acid bound to a protein such as casein glycomacropeptide or mucin; sialic acid bound to a carbohydrate such as sialyllactose or sialated bacterial capsular polysaccharides; and sialic acid bound to a lipid such as a ganglioside.
- the sialic acid is not bound to a protein, carbohydrate or lipid.
- the sialic acid is not bound to a protein. In some embodiments, the sialic acid is not a carbohydrate. In some embodiments, the sialic acid is not bound to a lipid. In some embodiments, the sialic acid is not part of a ganglioside or other glycolipid.
- sialic acid can be provided by providing a precursor of sialic acid that is metabolized to sialic acid.
- a sialic acid precursor can be N-acetylmannosamine, N-propanoylmannosamine, 2-keto-3-deoxynononic acid (KDN), N-glycolylneuraminic acid (Neu5Gc), the core sialic acid neuraminic acid molecule (Neu), or combinations thereof. See, e.g., Kontou et al., Biol. Chem. 2009; 390:575-579; and Gagiannis et al., Biochim Biophys Acta 2007; 1770:297-306.
- suitable sialic acid sources can be either natural or synthetic, and can include any of the naturally occurring and currently identified sialic acid derivatives, which can include free sialic acid, oligosaccharide conjugates (e.g., sialyloligosaccharides), lipid conjugates (e.g., glycolipids), protein conjugates (e.g., glycoproteins), and combinations thereof.
- oligosaccharide conjugates e.g., sialyloligosaccharides
- lipid conjugates e.g., glycolipids
- protein conjugates e.g., glycoproteins
- suitable sialic acid sources can include sialyloligosaccharides commonly found in human milk, whether natural or synthetic.
- the sialyloligosaccharides can be 3′sialyllactose (3′SL) and/or 6′sialyllactose (6′SL).
- Other suitable sialyloligosaccharides include, but are not limited to, those that contain one or more sialic acid molecules conjugated to oligosaccharides.
- sialic acids for use herein include, but are not limited to, any corresponding glycolipid that is also suitable for use in an infant formula, including, but not limited to, sphingosine, glucose, galactose, N-acetylgalactosamine, N-acetylglucosamine, and N-acetylneuraminic acid molecule.
- sialic acid compounds can also include, but are not limited to, any one or more of the several glycoproteins commonly found in human milk that are known to be sialylated (e.g., kappa-casein, alpha-lactalbumin, and lactoferrin).
- suitable sources of sialic acid can include isolates, concentrates, and/or extracts of mammalian milk or milk products, including, but not limited to, human and bovine milk.
- bovine milk can be a source for use herein, including, but not limited to, enriched whey protein concentrates as described herein.
- individual sources of sialic acid suitable for use herein can include, but are not limited to, Lacprodan CGMP-10 (casein glycomacropeptide with 4.2% sialic acid), available from Aria Food Ingredients, Denmark; and Biopure glycomacropeptide (with 7-8% sialic acid), available from Davisco Foods International, Eden Prairie, Minn., USA.
- sialic acid can be administered to a female in a composition or dosage form such as a nutritional supplement, food, pharmaceutical formulation, beverage or combinations thereof.
- a dosage form is a food, beverage and/or nutritional supplement.
- the dosage form is a food and/or beverage.
- the dosage form is a food.
- the dosage form is a nutritional supplement, including, but not limited to a prescription or nonprescription maternal prenatal vitamin. The preparations of such dosage forms are well known to persons of ordinary skill in the art.
- a sialic acid can be administered in a pharmaceutical formulation.
- pharmaceutical formulations include, but are not limited to, the dosage form is a chewable tablet, quick dissolve tablet, effervescent tablet, reconstitutable powder, elixir, liquid, solution, suspension, emulsion, tablet, multi-layer tablet, hi-layer tablet, capsule, soft gelatin capsule, hard gelatin capsule, caplet, lozenge, chewable lozenge, bead, powder, granule, particle, microparticle, dispersible granule, cachet, douche, suppository, cream, topical, inhalant, aerosol inhalant, patch, particle inhalant, implant, depot implant, ingestible, injectable, infusion, health bar, confection, cereal, cereal coating, nutritive food, functional food and/or combinations thereof.
- the preparations of such pharmaceutical formulations are well known to persons of ordinary skill in the art.
- the dosage form is a baked good and/or mix; chewing gum; breakfast cereal; cheese product; nut and/or nut product; gelatin, pudding, and/or filling; frozen dairy product; milk product; dairy product; soft candy; soup and/or soup mix; snack food; fruit juice; vegetable juice; fat and/or oil; fish product; plant protein product; poultry product; and/or meat product.
- the dosage form is a confectionary (e.g., chocolate) and/or fortified bar. The preparations of such dosage forms are well known to persons of ordinary skill in the art.
- the amount of sialic acid in a dosage form can vary according to factors such as the disease state, age, sex, and weight of the individual or female. Dosage regimens can be adjusted to provide an optimum sialic acid supplementation and/or developmental benefit. Dosage regimens can also be adjusted to contain varying levels of one or more sialic acid. In some embodiments, the varying levels of sialic acid can be adapted for each stage of preconception, pregnancy or postpartum.
- the specification for the dosage forms of the present invention can be dictated by or directly dependent on, for example, the unique characteristics of a particular sialic acid and the particular developmental benefit to be achieved.
- a dosage form useful in the methods of the invention can contain sialic acid in an amount of at least 0.01%, at least 0.1%, at least 0.2%, at least 0.3%, at least 0.4%, at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1.0%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or at least 99
- a dosage form useful in the methods of the invention can contain sialic acid in an amount of 0.01% to 20% by weight of the dosage form and, for example, can be a food and/or beverage. In some embodiments, a dosage form can contain sialic acid in an amount of 0.1% to 10% by weight of the dosage form and, for example, can be a food and/or beverage. In some embodiments, a dosage form can contain sialic acid in an amount of 1% to 5% by weight of the dosage form and, for example, can be administered in a food and/or beverage. In some embodiments, a dosage form can contain sialic acid in an amount of 0.01% to 1% by weight of the dosage form and, for example, can be administered in a food and/or beverage. In some embodiments, a dosage form can contain sialic acid in an amount of 0.01% to 99% by weight of the dosage form and, for example, can be administered in a food and/or beverage.
- a dosage form useful in the methods of the invention can contain sialic acid in an amount of 10% to 90% by weight of the dosage form and, for example, can be a nutritional supplement. In some embodiments, a dosage form can contain sialic acid in an amount of 20% to 80% by weight of the dosage form and, for example, can be a nutritional supplement. In some embodiments, a dosage form can contain sialic acid in an amount of 30% to 70% by weight of the dosage form and, for example, can be a nutritional supplement. In some embodiments, a dosage form can contain sialic acid in an amount of 40% to 60% by weight of the dosage form and, for example, can be a nutritional supplement.
- a dosage form can contain sialic acid in an amount of 70% to 90% by weight of the dosage form and, for example, can be a nutritional supplement. In some embodiments, a dosage form can contain sialic acid in an amount of 0.1% to 99% by weight of the dosage form and, for example, can be a nutritional supplement.
- the amount of sialic acid useful in the methods of the invention can be at least 20 mg/day, at least 25 mg/day, at least 30 mg/day, at least 35 mg/day, at least 40 mg/day, at least 45 mg/day, at least 50 mg/day, at least 55 mg/day, at least 60 mg/day, at least 70 mg/day, at least 75 mg/day, at least 80 mg/day, at least 85 mg/day, at least 90 mg/day, at least 100 mg/day, at least 110 mg/day, at least 120 mg/day, at least 125 mg/day, at least 130 mg/day, at least 140 mg/day, at least 150mg/day, at least 160 mg/day, at least 170 mg/day, at least 175 mg/day, at least 180 mg/day, at least 190 mg/day, at least 200 mg/day, at least 225 mg/day, at least 250 mg/day, at least 275 mg/day, at least 300 mg/day, at least 325 mg/day, at least
- sialic acid can be administered during one or more of the stages of preconception, pregnancy/gestation and during lactation/postpartum. In some embodiments, sialic acid can be administered during a stage of pregnancy/gestation. In some embodiments, sialic acid can be administered during stage I of pregnancy/gestation (the first trimester), stage II of pregnancy/gestation (the second trimester), and/or stage III of pregnancy/gestation (third trimester). In some embodiments, sialic acid can be administered during preconception, stage I of pregnancy/gestation (the first trimester), stage II of pregnancy/gestation (the second trimester), stage III of pregnancy/gestation and/or during lactation/postpartum.
- sialic acid can be administered during the first, second and/or third trimester and/or during lactation/postpartum. In other embodiments, sialic acid can be administered during the first, second, and/or third trimester. In some embodiments, sialic acid is administered can be administered during each stage of pregnancy. In some embodiments, sialic acid is administered continuously throughout each stage of pregnancy.
- sialic acid can be administered during preconception and/or the first trimester. In some embodiments, sialic acid can be administered during the second trimester. In some embodiments, sialic acid can be administered during the third trimester. In some embodiments, sialic acid can be administered during lactation/postpartum. In some embodiments, sialic acid can be administered postpartum to the female during the first two years following birth.
- a fetus is exposed to sialic acid by administration of sialic acid to a female pregnant with the fetus.
- sialic acid supplementation can have benefits for the female even if the female is not breast feeding a child.
- a sialic acid can be administered to the female and to a fetus or child.
- a fetus is exposed to sialic acid by administration of sialic acid to the biological mother of the fetus.
- a fetus is exposed to sialic acid by administration of sialic acid to a surrogate carrier of the fetus.
- the fetus is exposed to sialic acid during the first, second and third trimesters of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the first and second trimesters of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the second and third trimesters of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the first and third trimesters of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the first trimester of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the second trimester of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the third trimester of pregnancy.
- a child is exposed to sialic acid by feeding the child an infant formula containing sialic acid. In some embodiments, a child is exposed to sialic acid by feeding the child breast milk containing sialic acid, wherein the breast milk is from a female receiving sialic acid supplementation as described herein. In some embodiments, a child is exposed to sialic acid by feeding the child breast milk containing sialic acid, wherein the breast milk is from the biological mother of the child receiving sialic acid supplementation as described herein. In some embodiments, a child is exposed to sialic acid by feeding the child breast milk containing sialic acid, wherein the breast milk is from the surrogate carrier of the child receiving sialic acid supplementation as described herein.
- the child is exposed to sialic acid from birth to 5 years of age. In some embodiments, the child is exposed to sialic acid from birth to 4 years of age. In some embodiments, the child is exposed to sialic acid from birth to 3 years of age. In some embodiments, the child is exposed to sialic acid from birth to 2 years of age. In some embodiments, the child is exposed to sialic acid from birth to 1 year of age. In some embodiments, the child is exposed to sialic acid from 1 to 3 years of age. In some embodiments, the child is exposed to sialic acid from 1 to 2 years of age.
- sialic acid can be provided on a daily basis during all or most of the period of time from birth to about 24 months of age. In some embodiments, sialic acid can be provided on less than a daily basis for a time period of less than two years, as long as desirable results are obtained. In some embodiments, sialic acid can be administered to the female beginning in the first trimester, continuing throughout gestation, and during about the first two years of lactation/breastfeeding following birth.
- a dosage form comprises sialic acid and one or more excipients.
- an excipient can be, for example, one or more additional nutritional supplements and/or maternal prenatal vitamins, including, but not limited to, one or more polyunsaturated fatty acids, calcium, folic acid, vitamin E, tocotrienols, vitamin D, magnesium, phosphorus, vitamin K, iron, vitamin B12, niacin, thiamine, riboflavin, biotin, vitamin B6, and isoflavones, zinc, pantothenic acid, medium chain triglycerides, copper, manganese, magnesium, vitamin A, choline, vitamin C, iodine, selenium, prebiotics, probiotics, beta-carotene, lutein, lycopene, alpha-carotene, zeaxanthin, beta-cryptoxanthin, gamma carotene, ginger, and tryptophan.
- a composition or dosage form of the invention comprises sialic acid. In some embodiments, a composition or dosage form of the invention comprises sialic acid and infant formula. In some embodiments, a dosage form can comprise at least 0.1 mg, at least 1 mg, at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 85 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 105 mg, at least 110 mg, at least 115 mg, at least 120 mg, at least 125 mg, at least 130 mg, at least 135 mg, at least 140 mg, at least 145 mg, at least 150 mg, at least 200 mg, at least 250 mg, at least 300 mg, at least 350 mg, at least 400 mg, at least 450 mg, at least 500 mg
- a dosage form is administered to the female at least once a day, at least twice a day, at least three times a day, at least four times a day, at least five times a day, at least six times a day, at least seven times a day, at least eight times a day, at least nine times a day, or at least ten times a day.
- a dosage form is administered to the female from once to ten times a day.
- a dosage form is administered to the female from once to five times a day.
- a dosage form is administered to the female from one to three times a day.
- a female in preconception, pregnancy/gestation or lactation/postpartum receiving sialic acid supplementation can realize developmental benefits for a fetus and/or child.
- the developmental benefit can be improved nervous system growth and/or development or growth of the brain.
- the developmental benefit can be improved cognitive performance, earlier attainment of normal cognitive skills, improved motor skills, or earlier attainment of normal motor skills.
- the developmental benefit can be a structural improvement in the brain that can include, but is not limited to, one of more of the following: increased expression and/or development of mature myelin, enhanced neurite extension, increased levels of myelin basic protein at earlier developmental timepoints, and enhanced development of the white matter of the brain.
- an increased thickness of the myelin sheath and increased electrical conduction velocities can occur.
- the white matter can be the corpus callosum, the lateral olfactory tract, the motor pyramids, the medullary pyramids, and/or the pyramids, but any or all white matter regions of the brain can be involved.
- the developmental benefit can be enhanced development of the brain's hippocampus, which can include increased connectivity between brain cells, greater numbers of synapses, greater cell numbers, or longer cell survival times, but enhancement of these measures can be in any gray matter region of the brain (e.g., cerebral cortex, cerebellum, and all known nuclei of the brain).
- a developmental benefit is increased neurite extension (e.g., hippocampal) in the brain of the child or fetus.
- neurite extension with sialic acid supplementation is increased by at least 0.01%, at least 0.02%, at least 0.03%, at least 0.04%, at least 0.05%, at least 0.06%, at least 0.07%, at least 0.08%, at least 0.09%, at least 0.1%, at least 0.2%, at least 0.3%, at least 0.4%, at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 2
- neurite extension with sialic acid supplementation can be increased from 0.01% to 100%, 0.01% to 75%, 0.01% to 50%, 1% to 50%, 5% to 50%, 10% to 50%, 0.01% to 10%, 0.01% to 5%, 0.01% to 1%, 0.01% to 0.5%, 0.01% to 0.2% or 0.1% to 0.2%, compared to neurite extension without sialic acid supplementation.
- increased neurite extension is measured by immunocytochemistry for the neuron-specific marker, Map2a.
- increased neurite extension results from the administration of sialic acid to the female during preconception and/or pregnancy.
- increased neurite extension results from the administration of sialic acid to the female during lactation. In some embodiments, increased neurite extension results from the administration of sialic acid to the female during pregnancy and not during lactation. In some embodiments, increased neurite extension results from the administration of sialic acid to the female during lactation and not during pregnancy.
- a developmental benefit is increased levels of myelin basic protein (MBP) in the brain of the child or fetus.
- MBP expression in the brain e.g., whole brain, cerebellum, corpus callosum, frontal and/or rostral corpus callosum, middle corpus callosum, midline corpus callosum decussation, lateral olfactory tract, motor output pathways, sensory input pathways, motor pyramids, and/or medial lemniscus
- sialic acid supplementation is increased by at least 0.01%, at least 0.02%, at least 0.03%, at least 0.04%, at least 0.05%, at least 0.06%, at least 0.07%, at least 0.08%, at least 0.09%, at least 0.1%, at least 0.2%, at least 0.3%, at least 0.4%, at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1%, at least 2%, at least 3%, at least 0.4%, at least 0.5%
- MBP expression with sialic acid supplementation can be increased by 0.01% to 100%, 0.01% to 25%, 0.1% to 25%, 1% to 25%, 1% to 20%, 1% to 10%, 1% to 5%, or 5% to 20% compared to MBP expression without sialic acid supplementation.
- MBP expression is measured by immunocytochemistry.
- increased MBP expression results from the administration of sialic acid to the female during preconception and/or pregnancy. In some embodiments, increased MBP expression results from the administration of sialic acid to the female during lactation. In some embodiments, increased MBP expression results from the administration of sialic acid to the female during pregnancy and not during lactation. In some embodiments, increased MBP expression results from the administration of sialic acid to the female during lactation and not during pregnancy.
- MBP expression with sialic acid supplementation is increased in the corpus callosum, rostral corpus callosum, midline corpus callosum, lateral olfactory tract and/or midline corpus callosum decussation compared to MBP expression without sialic acid supplementation.
- MBP expression with sialic acid supplementation is increased in the corpus callosum, rostral corpus callosum, midline corpus callosum, lateral olfactory tract and/or midline corpus callosum decussation, and is not increased in the motor output pathways, sensory input pathways, motor pyramids and/or medial lemniscus compared to MBP expression without sialic acid supplementation.
- MBP expression with sialic acid supplementation is increased in the corpus callosum, rostral corpus callosum, midline corpus callosum, lateral olfactory tract and/or midline corpus callosum decussation, and is not increased in the motor output pathways, sensory input pathways, motor pyramids and/or medial lemniscus compared to MBP expression without sialic acid supplementation, and the sialic acid is administered to the female during pregnancy.
- MBP expression with sialic acid supplementation is increased in the corpus callosum, rostral corpus callosum, midline corpus callosum, lateral olfactory tract and/or midline corpus callosum decussation, and is not increased in the motor output pathways, sensory input pathways, motor pyramids and/or medial lemniscus compared to MBP expression without sialic acid supplementation, and the sialic acid is administered to the female during pregnancy and not during lactation.
- MBP expression with sialic acid supplementation is increased in the cerebellum compared to MBP expression without sialic acid supplementation. In some embodiments, MBP expression with sialic acid supplementation is increased in the cerebellum compared to MBP expression without sialic acid supplementation, and the sialic acid is administered during lactation. In some embodiments, MBP expression with sialic acid supplementation is increased in the cerebellum compared to MBP expression without sialic acid supplementation, and the sialic acid is administered during lactation and not during pregnancy.
- the sialic acid administered to a female at least in part crosses the blood brain barrier.
- the sialic acid administered to a female is N-acetylneuraminic acid (NANA), which at least in part crosses the blood brain barrier.
- the sialic acid administered to a female is NANA, which at least in part is converted into Neu5Gc in non-human animals.
- the sialic acid administered to a female is NANA, which at least in part crosses the blood brain barrier and is at least in part converted into Neu5Gc in non-human animals.
- the sialic acid administered to a female is present in the cerebrospinal fluid (CSF).
- the sialic acid administered to a female is NANA, and the NANA is present at least in part in the CSF.
- the sialic acid administered to a female is NANA, and the NANA is at least in part converted into Neu5Gc in non-human animals.
- the sialic acid administered to a female is NANA, and the NANA is present at least in part in the CSF and is at least in part converted into Neu5Gc in non-human animals.
- the invention relates to the use of any of the sialic acid compositions described herein in the preparation of a dosage form for any of the uses described herein.
- control animals were placed on a base diet (“Base” or “None”) which contained no detectable amounts of NANA throughout gestation and lactation.
- Base or “None”
- Darns placed on the gestational diet (“Gest”) received NANA (200 milligrams (mg) per kilogram (kg) body weight per day (d)) only during gestation.
- Gest was placed on the gestational diet
- d body weight per day
- Dams receiving NANA (200 mg/kg/d) through the diet throughout gestation and lactation were known as the “G+L” group.
- FIG. 2 also shows how and when the offspring were used to determine the effects of the maternal diets on offspring development.
- the pups born to each diet group were crossfostered within their respective group to control for any differences in maternal care.
- the litters were then culled to 10 pups per dam to prevent nutritional differences caused by lack of access to the dam.
- Pups were taken at postnatal day 16 (p16) because they begin to access the mother's food directly at ⁇ p18, which would preclude any assessment of maternal transfer of NANA to the pups. Pups were also taken at p8 because it served as a midway timepoint and because the primary biomarker used cannot be detected until this day in rat development.
- FIGS. 3A and 3B show the maternal NANA supplementation protocol for experiments testing additional doses of NANA administered during gestation ( FIG. 3A ) and lactation ( FIG. 3B ).
- MBP myelin basic protein
- MBP expression is a measure of brain development because it is a specific measure of the degree of mature myelination of the brain's circuitry.
- Myelin is the insulation between the “wires” of the brain and decreases electrical resistance in the brain's circuits much in the same way that insulation decreases electrical resistance in copper wiring. Decreased resistance allows for better signaling and subsequent developmental differentiation. Thus, the expression levels of mature myelin are associated with brains that are farther along in development.
- MBP expression was measured by western blot analysis of whole brain lysates that were harvested from pups at postnatal days 0, 8, and 16 described in FIG. 2 .
- the blots were probed with an antibody for MBP (lower panels; Millipore, Billerica, Mass. or Covance, Princeton, N.J.) that recognizes two distinct isoforms (18 and 21 kilodaltons [kDa] in molecular weight).
- the blots were also probed with an antibody for ⁇ -actin (upper panels; Cell Signaling Technologies, Beverly, Mass. or Millipore, Billerica, Mass.) that served as protein loading controls.
- the hippocampus is a specific region of the brain that is essential for spatial learning and for moving short-term memories into long-term memory.
- Neurite extension in cultures of the hippocampus serves as a measure of brain cell growth, differentiation, and networking. Increases in these ex vivo measures are considered beneficial because it is believed that similar beneficial processes occur in vivo.
- FIG. 5A shows the measurements of offspring of dams exposed to a NANA-deficient diet during gestation.
- FIG. 5B shows the measurements of offspring of dams that were fed a NANA-supplemented (200 mg/kg/d) diet during gestation. After 6 days of incubation the cultures underwent immunocytochemistry for the neuron-specific marker, Map2a (Sigma, Ronkonkoma, NY; or Millipore, Billerica, Mass.). The number of cells in each culture was assessed by staining with 4′,6-diamidino-2-phenylindole (DAPI).
- Map2a Sigma, Ronkonkoma, NY; or Millipore, Billerica, Mass.
- FIG. 6A shows representative hippocampal cultures derived from offspring of dams having a NANA-deficient diet during gestation (“no NANA”) or a NANA-supplemented (25 mg/kg/d NANA, 50 mg/kg/d NANA, 100 mg/kg/d NANA, and 200 mg/kg/d NANA) diet during gestation.
- the percent area of Map2a staining per neuron was quantitated as described in Example 3. As shown in FIG. 6B , the percent area of Map2a staining per neuron was significantly greater in cultures derived from pups whose mothers had received NANA in their diets (**, p ⁇ 0.01; ***, p ⁇ 0.001). Thus, maternal exposure to NANA significantly increased neurite extension in hippocampal cultures of the offspring.
- the corpus callosum (CC) is the major tract for communication between the two cerebral hemispheres that control executive function and learning
- the lateral olfactory tract (LOT) is particularly important in rodents because they rely largely on their olfactory system for orientation and food-guided behavior in their normal environments.
- the LOT carries information from the primary olfaction centers of the olfactory bulbs to higher processing centers in the cerebrum and hippocampus.
- the CC and LOT were measured in the following experiments because of their size and because of their importance in brain function and in the animals' abilities to sense their environments
- FIG. 7C shows maternal NANA supplementation also resulted in significant increases to the maximal thickness of MBP expression in the LOT which were similar to those detected in the CC. Furthermore, these findings were consistent with the Western blot findings described in Example 2.
- FIG. 8A shows maternal NANA supplementation during gestation resulted in significant increases to the thickness of MBP expression in the frontal CC in the offspring (***, p ⁇ 0.001).
- FIG. 8B shows maternal NANA supplementation did not appear to change the thickness of MBP expression in the middle CC.
- FIG. 8C shows maternal NANA supplementation resulted in significant increases to the thickness of MBP expression in the LOT (*, p ⁇ 0.05; ***, p ⁇ 0.001).
- FIG. 8D shows maternal NANA supplementation did not appear to change the thickness of MBP expression in the midline CC decussation.
- the white matter of the spinal cord contains tracts of fibers that are ascending (sensory) or descending (motor).
- the ascending tracts convey sensory information from cutaneous receptors, proprioceptors (muscle and joint senses) and visceral receptors.
- the medial lemniscus is a pathway that carries such sensory information from the gracile and cuneate nuclei to the thalamus.
- FIG. 9A shows maternal NANA supplementation during gestation resulted in significant increases to the thickness of MBP expression in the motor pyramids in the offspring (*, p ⁇ 0.05; **, p ⁇ 0.01; ***, p ⁇ 0.001).
- FIG. 9B shows maternal NANA supplementation resulted in significant increases to the thickness of MBP expression in the medial lemniscus (*, p ⁇ 0.05; **, p ⁇ 0.01).
- FIG. 10A shows maternal NANA supplementation during lactation resulted in significant increases to the thickness of MBP expression in the rostral CC in the offspring (**, p ⁇ 0.01; ***, p ⁇ 0.001).
- FIG. 10B shows maternal NANA supplementation during lactation resulted in significant increases to the thickness of MBP expression in the midline CC in the offspring (**, p ⁇ 0.01; ***, p ⁇ 0.001).
- FIG. 10C shows maternal NANA supplementation during lactation resulted in significant increases to the thickness of MBP expression in the LOT in the offspring (***, p ⁇ 0.001).
- FIG. 10D shows maternal NANA supplementation during lactation resulted in significant increases to the thickness of MBP expression in the midline CC decussation in the offspring (*, p ⁇ 0.05; ***, p ⁇ 0.001).
- FIG. 11B shows maternal NANA supplementation during lactation resulted in no significant changes to the thickness of MBP expression in the medial lemniscus in the offspring.
- MEW expression was measured by western blot analysis of cerebellum that was harvested from pups at postnatal days 0, 8, and 16 described in FIG. 3B .
- the blots were probed with an antibody for MBP as described in Example 2 that recognizes the 18 kilodalton form (18 kD MBP) and 21 kilodalton form (21 kD MBP) and an antibody for ⁇ -actin as a protein loading control.
- Quantitation of MBP expression performed with densitometry of the bands in each lane, and each lane represented an individual animal as described in Example 2.
- the graphs in FIGS. 12A and 12B represent the average intensity of MBP expression normalized by the corresponding actin signal in relative fluorescence units (Normalized R.F.U.).
- ANOVA One-way analysis of variance (ANOVA) detected a significant increase the expression of both 18 kDa MBP and 21 kDa MBP with NANA supplementation during lactation at certain doses tested (p ⁇ 0.001).
- NANA cerebrospinal fluid
- the animals' diets were first cleared of NANA by placing them on NANA-flee diets for one week.
- the animals were then given a single, oral dose of NANA (200 mg/kg), and the CSF of each animal was sampled at 0, 0.25, 1, 2, 4, and 6 hours after dosing.
- the concentrations of NANA and Neu5Gc in the CSF were then assessed by high-pressure liquid chromatography coupled with fluorescence detection methods and quantitation standards.
- FIG. 13 illustrates the changes in the concentrations of NANA and Neu5Gc in the CSF after oral NANA dosing.
- FIG. 13A shows, a peak of native NANA was detectable above baseline 15 minutes after dosing. This NANA peak then decayed relatively rapidly and returned to baseline values by 1 hour after oral NANA dosing.
- the Neu5Gc concentrations did not increase above baseline until 1 hour after oral dosing, and this increase was noticeably after the NANA peak observed at 15 minutes after dosing.
- the Neu5Gc concentrations were then sustained throughout the rest of the sampling period at levels that were approximately 4% of the peak NANA concentration.
- exogenous NANA is bioavailable to the brain, but it is also processed to some extent. It should be noted here that, unlike all other mammals, humans do not possess a functional enzyme for converting NANA to Neu5Gc, so the data would likely be different in human CSF.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pediatric Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention provides methods and compositions for improving fetal and child health and development through nutritional supplementation with, for example, sialic acid. Sialic acid can be provided to a female before, during and/or after pregnancy to improve the health and development of a fetus and/or child. The sialic acid can be in a variety of forms in the supplements.
Description
- This application is a continuation of U.S. application Ser. No. 13/634,467 (pending), filed Nov. 20, 2012 (published as US-2013-0137643-A1), which is a U.S. national phase of International Application No. PCT/US2011/028068 filed 11 Mar. 2011 which designated the U.S. and claims priority to U.S. Provisional Application No. 61/313,630 filed 12 Mar. 2010, the entire contents of each of which is hereby incorporated by reference.
- 1. Field of the Invention
- The invention relates to supplements containing sialic acid and the use of such supplements for a female that can result in developmental benefits for a fetus and/or child.
- 2. Background Art
- The rapid growth and development of a fetus or child places significant demand on the maternal supply of nutrients. See, e.g., Crawford et al., Eur. J. Pediatr. 1998; 157:23-27. Nutrient deficits have profound effects on the growth and structural/functional development of the fetus or child, particularly in the growth and development of the brain. Brain growth, including cell number and structural and synaptic connectivity, reaches its peak at 26 weeks of gestation and continues at a high rate throughout the first year of life. This period of brain growth is critical because once the period has passed, it cannot be restarted. Furthermore, this period of growth is particularly important in premature infants. See, e.g., Crawford et al., Eur. J. Pediatr. 1998; 157:23-27.
- Numerous studies indicate that breast-fed infants achieve better cognitive development and attain higher scores on intelligence tests than bottle-fed babies. See, e.g., Mortensen et al., JAMA 2002; 287:2365-2371. For example, intelligence quotient (IQ) has been shown to increase in infants receiving a longer duration of breastfeeding, particularly in low birth weight infants. See, e.g., Anderson et al., Am. J. Clin. Nutr. 1999; 70:525-535.
- Complex lipids from gangliosides, as well as long-chain polyunsaturated fatty acids (LCPUFAs) such as docosahexaenoic acid (DHA), are present in human milk and have been implicated in the improvement of visual acuity and cognitive ability in children. See, e.g., International Publication No. WO 2009/051502 A1 and Gibson, Lancet 1999; 354:1919-1920. However, other components of human milk might be important to brain growth and development of a fetus or child. These factors, such as enzymes, hormones, growth factors, and sialic acid, are found in human milk and are typically poorly represented in infant formulas. See, e.g., McVeagh and Miller, J. Paediatr. Child Health 1997; 33:281-286.
- Of the factors described above, sialic acid has been shown to have a simultaneous presence in significant amounts in both human milk and human brain. See, e.g., McVeagh and Miller, J. Paediatr. Child Health 1997; 33:281-286. Sialic acid is a generic term for the N- or O-substituted derivatives of neuraminic acid, a monosaccharide with a nine-carbon backbone, that are a structural and functional component of gangliosides. See, e.g., Varki and Schauer (2009) in Essentials of Glycobiology. 2nd ed., Cold Spring Harbor Press. Ch. 14; and
FIG. 1 . The most predominant sialic acid found in mammals is N-acetylneuraminic acid (NANA). - Certain roles for sialic acid in development and disease pathology have been described. For example, inactivation of the gene encoding an enzyme of sialic acid biosynthesis, uridine diphospho-N-acetylglucosamine (UDP-GlcNAc) 2-epimerase/N-acetylmannosamine (MacNAc) kinase (GNE/MNK), has been correlated with reduced sialic acid levels and the development of hereditary inclusion body myopathy (HIBM), an adult-onset progressive neuromuscular disorder. See, e.g., Galeano et al., J. Clin. Invest. 2007; 117:1585-1594; Malicdan et al., Nature Med. 2009; 15:690-695; and Huizing and Krasnewich, Biochim. Biophys. Acta 2009; 1792:881-887. Also, inactivation of the UDP-GlcNAc/MacNAc gene has been described to result in early embryonic lethality in mice, suggesting a role for the UDP-GlcNAc/MacNAc gene in development. See, e.g., Schwarzkopf et al., PNAS 2002; 99:5267-5270. The use of sialic acid to support the immune system and re-establish central and peripheral nervous system health in the elderly has also been described. See, e.g., European Patent Application Nos. 2116140 A1 and 2116139 A1.
- A mother's increased intake of some nutrients (e.g., docosahexaenoic acid) can benefit her child's brain development. However, there has been no evidence that the quantity of sialic acid a mother naturally makes is inadequate. As shown in the Examples, maternal supplementation with sialic acid clearly resulted in developmental benefits for a fetus or child, suggesting that maternal supplementation with sialic acid is needed. The present invention addresses this need by providing sialic acid which can be administered to a female during preconception, pregnancy/gestation and/or lactation/postpartum as described herein.
- While maternal supplementation with NANA has not been previously described, Hedlund et al. (Mol. Cell. Biol. 2007; 27:4340-4346) reported feeding another sialic acid, N-glycolylneuraminic acid (Neu5Gc), to mice lacking the gene to produce Neu5Gc. The researchers reported that feeding Neu5Gc to dams lacking this gene does not transfer Neu5Gc to pups that also lack the gene. In addition, adult mammals are known to readily synthesize sufficient levels of sialic acid and there is no clear evidence regarding whether or not the mother supplies sialic acid to the fetus through the matemoplacental unit. See, e.g., Briese et al., Z. Geburtsh. Neonatol. 1999; 203:63-68.
- The most rapid rate of brain development (“the brain growth spurt”) occurs during gestation and extends to at least the end of the first year of life. As such, the present invention optimizes the developmental benefits of maternal supplements such as sialic acid for a fetus or child by providing supplementation during this critical period of brain development.
- The present invention is directed to compositions and methods for providing sialic acid to a female, comprising the administration of sialic acid to the female during at least one of the stages of preconception, pregnancy and lactation. In some embodiments, the sialic acid provides a developmental benefit to a fetus or child of the female. In some embodiments, the sialic acid is a free sialic acid. In some embodiments, the sialic acid is selected from the group consisting of: oligosaccharide conjugates, lipid conjugates, protein conjugates, and combinations thereof. In some embodiments, the sialic acid is selected from the group consisting of: 3′sialyllactose, gangliosides, and casein glycomacropeptide. in some embodiments, the sialic acid is in the form of n-acetylneuraminic acid.
- In some embodiments, the sialic acid is a sialic acid precursor that is metabolized into sialic acid. In some embodiments, the sialic acid precursor is selected from the group consisting of: N-acetylmannosamine, N-propanoylmannosamine, 2-keto-3-deoxynononic acid, N-glycolylneuraminic acid, and the core sialic acid neuraminic acid molecule.
- In some embodiments, the sialic acid is administered during pregnancy and lactation. In some embodiments, the sialic acid is administered during preconception, pregnancy and lactation. In some embodiments, the sialic acid is administered during about the first two years following birth.
- In some embodiments, the developmental benefit is improved nervous system growth and/or development or growth of the brain of the fetus or child. In some embodiments, the developmental benefit is a neurological improvement of the brain. In some embodiments, the developmental benefit is selected from the group consisting of: increased expression and/or development of mature myelin, enhanced neurite extension, increased levels of myelin basic protein, and enhanced development the white matter of the brain. In some embodiments, the developmental benefit is in the gray matter of the brain.
- In some embodiments, the sialic acid is administered to the female in a dosage form. In some embodiments, the dosage form is selected from the group consisting of: nutritional supplements, foods, pharmaceutical formulations, beverages and combinations thereof. In some embodiments, the dosage form contains sialic acid at an amount of 0.01% to 10% by weight of the dosage form. In some embodiments, the dosage form contains sialic acid at an amount of 10% to 90% by weight of the dosage form.
- In some embodiments, the sialic acid is administered to the female at an amount of 5 mg/kg/day to 200 mg/kg/day of the female's body weight. In some embodiments, the sialic acid is administered at an amount of 25 mg/kg/day to 100 mg/kg/day of the female's body weight. In some embodiments, the sialic acid is administered at an amount of 20 mg/day to 4000 mg/day. In some embodiments, the sialic acid is administered at an amount of 200 mg/day to 2000 mg/day.
- In some embodiments, the methods further comprise administering the sialic acid to the female in a dosage form comprising sialic acid and an excipient. An excipient can be, for example, one or more of polyunsaturated fatty acids, calcium, folic acid, vitamin E, tocotrienols, vitamin D, magnesium, phosphorus, vitamin K, iron, vitamin B12, niacin, thiamine, riboflavin, biotin, vitamin B6, and isoflavones, zinc, pantothenic acid, medium chain triglycerides, copper, manganese, magnesium, vitamin A, choline, vitamin C, iodine, selenium, prebiotics, probiotics, beta-carotene, lutein, lycopene, alpha-carotene, zeaxanthin, beta-cryptoxanthin, gamma carotene, ginger, and tryptophan.
- The present invention will be more fully understood and appreciated by the following Detailed Description in conjunction with the accompanying drawings.
-
FIG. 1 is a schematic depicting members of the sialic acid family. - FIGS. 2 and 3A-3B show the dietary regimens of rats receiving sialic acid-supplemented diets, the effects of which are described in the Examples.
-
FIGS. 4A-4B show the effects of maternal sialic acid supplementation on the expression of myelin basic protein (MBP), normalized to β-actin expression, in the brains of the developing offspring (rat). -
FIGS. 5A-5C and 6A-6B show the effects of maternal sialic acid supplementation on neurite extension in cultures of hippocampal cells derived from the offspring. -
FIGS. 7A-7C , 8A-8D, 9A-9B, 10A-10D, 11A-11B and 12A-12B show the effects of sialic acid supplementation on the thickness (FIGS. 7-11 ) or levels (FIG. 12 ) of MBP expression in specific regions of the developing rat brain. -
FIGS. 13A-13B show NANA and Neu5Gc concentrations in cerebrospinal fluid (CSF) following NANA administration. - The present invention provides methods and compositions for improving female, fetal and/or child health and development through nutritional supplementation with, for example, sialic acid. In some embodiments, sialic acid can be administered to a female before, during and/or after pregnancy to improve the health and development of a fetus and/or child, including the developmental benefits described further herein. The sialic acid can be in a variety of forms in the supplements, including the dosage foams described further herein.
- As used herein, a “child” of the present invention, includes, but is not limited to, an individual or subject of any sex that is of an age between the time of delivery to approximately two years after delivery or to the time that breastfeeding has stopped, whichever is longer. This term includes infants and toddlers.
- As used herein, a “female” of the present invention includes, but is not limited to, an individual or subject that is the biological mother of a fetus or child, a surrogate carrier of a fetus, and an individual or subject that breastfeeds a child. This term also includes an individual or subject that is attempting to become pregnant.
- As used herein, a “maternal supplement” of the present invention can be administered to and useful for any female described herein.
- As used herein, “breastfeeding” includes, but is not limited to, feeding from a female's breast (e.g., nursing) and feeding a child breast milk from a bottle (e.g., bottlefeeding). This includes a female who both breastfeeds and feeds infant formula to her child (e.g., partial breastfeeding).
- As used herein, the term “sialic acid” refers to any member alone, or in combination with one or more other members, of the known family of derivatives of the nine-carbon sugar neuraminic acid. This term includes any sialic acid substitutions or variants and any precursors for sialic acid known in the art and described herein. This term includes conjugated and non-conjugated forms of sialic acid and free sialic acid. In some embodiments, the sialic acid is N-acetylneuraminic acid.
- As used herein, “sialic acid supplementation” refers to administration of sialic acid to a female resulting in a developmental benefit for a fetus and/or child.
- As used herein, a “precursor of sialic acid” or “sialic acid precursor” refers to a compound that is metabolized to faun sialic acid. In embodiments, a sialic acid precursor can include, but is not limited to, N-acetylmannosamine, N-propanoylmannosamine, 2-keto-3-deoxynononic add (KDN), N-glycolylneuraminic acid (Neu5Gc), the core sialic acid neuraminic acid molecule (Neu), and combinations thereof.
- As used herein, a “developmental benefit” refers to an improvement in a factor related to the development or growth of a fetus or child. Developmental benefits of a fetus or child can include one or more of, but are not limited to, enhanced nervous system growth and/or development, neurological improvements, increased expression and/or development of mature myelin, increased neurite extension (e.g., in the hippocampus), increased levels of myelin basic protein (e.g., in the whole brain, cerebellum, corpus callosum, frontal and/or rostral corpus callosum, middle corpus callosum, midline corpus callosum decussation, lateral olfactory tract, motor output pathways, sensory input pathways, motor pyramids, and/or medial lemniscus), increased development of white matter (e.g., in the corpus callosum, lateral olfactory tract, or other white matter tracts as described above but not limited to the above), and enhanced hippocampal development, as described further herein.
- As used herein, “preconception” refers to the period during which a female is attempting to become pregnant. In some embodiments, administration of sialic acid during preconception is useful for the period of time from conception to when a female realizes she is pregnant or when a pregnancy is confirmed.
- As used herein, the terms “pregnancy/gestation,” “pregnancy” and “gestation” refer to the period of time from conception to the delivery of a fetus. The stages of pregnancy/gestation include stage I (the first trimester), stage II (the second trimester) and stage III (third trimester).
- As used herein, the terms “lactation/postpartum,” “lactation” and “postpartum” refer to the period of time from the delivery of a fetus to approximately two years after delivery or to the time that breastfeeding is stopped.
- Sialic acid includes a family of over 50 known derivatives of the nine-carbon sugar neuraminic acid (5-amino-3,5-dideoxy-D-glycero-D-galacto-nonulsonic acid). See, e.g., Schauer, Glycoconj. J. 2000; 17:485-499 and
FIG. 1 . As an individual compound or moiety, sialic acid is a 9 carbon amino sugar, the structure of which is readily described in the chemical literature. See, e.g., Kontou et al., Biol. Chem. 2009; 390:575-579. One branch of the sialic acid family is N-acetylated to form N-acetylneuraminic acid, which is the most widespread form of sialic acid in humans. See, e.g., Kontou et al., Biol. Chem. 2009; 390:575-579. Other generally accepted names for N-acetylneuraminic acid include sialic acid; O-Sialic acid; 5-Acetamido-3,5-dideoxy-D-glycero-D-galacto-2-nonulosonic acid; 5-Acetamido-3,5-dideoxy-D-glycero-D-galactonulosonic acid; Aceneuramic acid; N-acetyl-neuraminate; N-Acetylneuraminic acid; NANA; and Neu5Ac. - Sialic acid molecules can be substituted in more than one position, with O-substitution occurring at C4, -7, -8 and -9 (O-acetyl, O-methyl, O-sulphate, and phosphate groups) and the introduction of a double bond between C-2 and C-3 can give rise to a wide variety of possible isomers. See, e.g., Kontou et al., Biol. Chem. 2009; 390:575-579 and
FIG. 1 . Another modification is the presence of a hydroxyl group instead of an amino group at position 5 of the sugar, leading to 2-keto-3-deoxy-nonulosonic acid (KDN), which has been found in fish eggs and red blood cells. See, e.g., Kontou et al., Biol. Chem. 2009; 390:575-579 and Inoue et al., J. Biol. Chem. 1998; 273:27199-27204. - Any source of sialic acid can be used in the compositions and methods of the present invention, including, but not limited to, animal, plant and microbial sources. Exemplary sources include, but are not limited to, sialic acid in monomeric or linked forms such as monomeric N-acetyl-neuraminic acid or polysialic acid; sialic acid bound to a protein such as casein glycomacropeptide or mucin; sialic acid bound to a carbohydrate such as sialyllactose or sialated bacterial capsular polysaccharides; and sialic acid bound to a lipid such as a ganglioside. In some embodiments, the sialic acid is not bound to a protein, carbohydrate or lipid. In some embodiments, the sialic acid is not bound to a protein. In some embodiments, the sialic acid is not a carbohydrate. In some embodiments, the sialic acid is not bound to a lipid. In some embodiments, the sialic acid is not part of a ganglioside or other glycolipid.
- In some embodiments, sialic acid can be provided by providing a precursor of sialic acid that is metabolized to sialic acid. In some embodiments, a sialic acid precursor can be N-acetylmannosamine, N-propanoylmannosamine, 2-keto-3-deoxynononic acid (KDN), N-glycolylneuraminic acid (Neu5Gc), the core sialic acid neuraminic acid molecule (Neu), or combinations thereof. See, e.g., Kontou et al., Biol. Chem. 2009; 390:575-579; and Gagiannis et al., Biochim Biophys Acta 2007; 1770:297-306.
- In some embodiments, suitable sialic acid sources can be either natural or synthetic, and can include any of the naturally occurring and currently identified sialic acid derivatives, which can include free sialic acid, oligosaccharide conjugates (e.g., sialyloligosaccharides), lipid conjugates (e.g., glycolipids), protein conjugates (e.g., glycoproteins), and combinations thereof.
- In some embodiments, suitable sialic acid sources can include sialyloligosaccharides commonly found in human milk, whether natural or synthetic. In some embodiments, the sialyloligosaccharides can be 3′sialyllactose (3′SL) and/or 6′sialyllactose (6′SL). Other suitable sialyloligosaccharides include, but are not limited to, those that contain one or more sialic acid molecules conjugated to oligosaccharides.
- Other suitable sialic acids for use herein include, but are not limited to, any corresponding glycolipid that is also suitable for use in an infant formula, including, but not limited to, sphingosine, glucose, galactose, N-acetylgalactosamine, N-acetylglucosamine, and N-acetylneuraminic acid molecule. Such sialic acid compounds can also include, but are not limited to, any one or more of the several glycoproteins commonly found in human milk that are known to be sialylated (e.g., kappa-casein, alpha-lactalbumin, and lactoferrin).
- In some embodiments, suitable sources of sialic acid can include isolates, concentrates, and/or extracts of mammalian milk or milk products, including, but not limited to, human and bovine milk. In some embodiments, bovine milk can be a source for use herein, including, but not limited to, enriched whey protein concentrates as described herein. In some embodiments, individual sources of sialic acid suitable for use herein can include, but are not limited to, Lacprodan CGMP-10 (casein glycomacropeptide with 4.2% sialic acid), available from Aria Food Ingredients, Denmark; and Biopure glycomacropeptide (with 7-8% sialic acid), available from Davisco Foods International, Eden Prairie, Minn., USA.
- In some embodiments, sialic acid can be administered to a female in a composition or dosage form such as a nutritional supplement, food, pharmaceutical formulation, beverage or combinations thereof. In some embodiments, a dosage form is a food, beverage and/or nutritional supplement. In some embodiments, the dosage form is a food and/or beverage. In some embodiments, the dosage form is a food. In some embodiments, the dosage form is a nutritional supplement, including, but not limited to a prescription or nonprescription maternal prenatal vitamin. The preparations of such dosage forms are well known to persons of ordinary skill in the art.
- In some embodiments, a sialic acid can be administered in a pharmaceutical formulation. Examples of such pharmaceutical formulations include, but are not limited to, the dosage form is a chewable tablet, quick dissolve tablet, effervescent tablet, reconstitutable powder, elixir, liquid, solution, suspension, emulsion, tablet, multi-layer tablet, hi-layer tablet, capsule, soft gelatin capsule, hard gelatin capsule, caplet, lozenge, chewable lozenge, bead, powder, granule, particle, microparticle, dispersible granule, cachet, douche, suppository, cream, topical, inhalant, aerosol inhalant, patch, particle inhalant, implant, depot implant, ingestible, injectable, infusion, health bar, confection, cereal, cereal coating, nutritive food, functional food and/or combinations thereof. The preparations of such pharmaceutical formulations are well known to persons of ordinary skill in the art.
- In some embodiments, the dosage form is a baked good and/or mix; chewing gum; breakfast cereal; cheese product; nut and/or nut product; gelatin, pudding, and/or filling; frozen dairy product; milk product; dairy product; soft candy; soup and/or soup mix; snack food; fruit juice; vegetable juice; fat and/or oil; fish product; plant protein product; poultry product; and/or meat product. In some embodiments, the dosage form is a confectionary (e.g., chocolate) and/or fortified bar. The preparations of such dosage forms are well known to persons of ordinary skill in the art.
- The amount of sialic acid in a dosage form can vary according to factors such as the disease state, age, sex, and weight of the individual or female. Dosage regimens can be adjusted to provide an optimum sialic acid supplementation and/or developmental benefit. Dosage regimens can also be adjusted to contain varying levels of one or more sialic acid. In some embodiments, the varying levels of sialic acid can be adapted for each stage of preconception, pregnancy or postpartum. The specification for the dosage forms of the present invention can be dictated by or directly dependent on, for example, the unique characteristics of a particular sialic acid and the particular developmental benefit to be achieved.
- In some embodiments, a dosage form useful in the methods of the invention can contain sialic acid in an amount of at least 0.01%, at least 0.1%, at least 0.2%, at least 0.3%, at least 0.4%, at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1.0%, at least 1.5%, at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or at least 99.5% by weight of the dosage form, and useful ranges can be selected between any of these values, e.g., from 0.01% to 99%, 0.01% to 1%, 0.1% to 10%, 0.5% to 10%, 1% to 5%, 5% to 25%, 5% to 95%, 5% to 80%, 10% to 95%, 15% to 95%, 20% to 95%, 25% to 95%, 30% to 95%, 35% to 95%, 40% to 95%, 45% to 95%, 50% to 95%, 1% to 99%, 5% to 99%, 10% to 99%, 15% to 99%, 20% to 99%, 25% to 99%, 30% to 99%, 35% to 99%, 40% to 99%, 45% to 99%, 50% to 99%, 5% to 70%, 10% to 70%, 15% to 70%, 20% to 70%, 25% to 70%, 30% to 70%, 35% to 70%, 40% to 70%, 45% to 70%, and 50% to 70% by weight of the dosage form.
- In some embodiments, a dosage form useful in the methods of the invention can contain sialic acid in an amount of 0.01% to 20% by weight of the dosage form and, for example, can be a food and/or beverage. In some embodiments, a dosage form can contain sialic acid in an amount of 0.1% to 10% by weight of the dosage form and, for example, can be a food and/or beverage. In some embodiments, a dosage form can contain sialic acid in an amount of 1% to 5% by weight of the dosage form and, for example, can be administered in a food and/or beverage. In some embodiments, a dosage form can contain sialic acid in an amount of 0.01% to 1% by weight of the dosage form and, for example, can be administered in a food and/or beverage. In some embodiments, a dosage form can contain sialic acid in an amount of 0.01% to 99% by weight of the dosage form and, for example, can be administered in a food and/or beverage.
- In some embodiments, a dosage form useful in the methods of the invention can contain sialic acid in an amount of 10% to 90% by weight of the dosage form and, for example, can be a nutritional supplement. In some embodiments, a dosage form can contain sialic acid in an amount of 20% to 80% by weight of the dosage form and, for example, can be a nutritional supplement. In some embodiments, a dosage form can contain sialic acid in an amount of 30% to 70% by weight of the dosage form and, for example, can be a nutritional supplement. In some embodiments, a dosage form can contain sialic acid in an amount of 40% to 60% by weight of the dosage form and, for example, can be a nutritional supplement. In some embodiments, a dosage form can contain sialic acid in an amount of 70% to 90% by weight of the dosage form and, for example, can be a nutritional supplement. In some embodiments, a dosage form can contain sialic acid in an amount of 0.1% to 99% by weight of the dosage form and, for example, can be a nutritional supplement.
-
- In some embodiments, the amount of sialic acid useful in the methods of the invention can be at least 2 mg/kg/day, at least 3 mg/kg/day, at least 5 mg/kg/day, at least 10 mg/kg/day, at least 15 mg/kg/day, at least 20 mg/kg/day, at least 25 mg/kg/day, at least 30 mg/kg/day, at least 35 mg/kg/day, at least 40 mg/kg/day, at least 45 mg/kg/day, at least 50 mg/kg/day, at least 55 mg/kg/day, at least 60 mg/kg/day, at least 65 mg/kg/day, at least 70 mg/kg/day, at least 75 mg/kg/day, at least 80 mg/kg/day, at least 85 mg/kg/day, at least 90 mg/kg/day, at least 95 mg/kg/day, at least 100 mg/kg/day, at least 105 mg/kg/day, at least 110 mg/kg/day, at least 115 mg/kg/day, at least 120 mg/kg/day, at least 125 mg/kg/day, at least 130 mg/kg/day, at least 135 mg/kg/day, at least 140 mg/kg/day, at least 145 mg/kg/day, at least 150 mg/kg/day, at least 155 mg/kg/day, at least 160 mg/kg/day, at least 165 mg/kg/day, at least 170 mg/kg/day, at least 175 mg/kg/day, at least 180 mg/kg/day, at least 185 mg/kg/day, at least 190 mg/kg/day, at least 195 mg/kg/day, or at least 200 mg/kg/day of the female's body weight, and useful ranges can be selected between any of these values, e.g., from 2 mg/kg/day to 200 mg/kg/day, 3 mg/kg/day to 200 mg/kg/day, 5 mg/kg/day to 200 mg/kg/day, 10 mg/kg/day to 175 mg/kg/day, 25 mg/kg/day to 150 mg/kg/day, 50 mg/kg/day to 100 mg/kg/day, 5 mg/kg/day to 75 mg/kg/day, 10 mg/kg/day to 75 mg/kg/day, 3 mg/kg/day to 50 mg/kg/day, and 25 mg/kg/day to 50 mg/kg/day.
- In some embodiments, the amount of sialic acid useful in the methods of the invention can be at least 20 mg/day, at least 25 mg/day, at least 30 mg/day, at least 35 mg/day, at least 40 mg/day, at least 45 mg/day, at least 50 mg/day, at least 55 mg/day, at least 60 mg/day, at least 70 mg/day, at least 75 mg/day, at least 80 mg/day, at least 85 mg/day, at least 90 mg/day, at least 100 mg/day, at least 110 mg/day, at least 120 mg/day, at least 125 mg/day, at least 130 mg/day, at least 140 mg/day, at least 150mg/day, at least 160 mg/day, at least 170 mg/day, at least 175 mg/day, at least 180 mg/day, at least 190 mg/day, at least 200 mg/day, at least 225 mg/day, at least 250 mg/day, at least 275 mg/day, at least 300 mg/day, at least 325 mg/day, at least 350 mg/day, at least 375 mg/day, at least 400 mg/day, at least 425 mg/day, at least 450 mg/day, at least 475 mg/day, at least 500 mg/day, at least 525 mg/day, at least 550 mg/day, at least 575 mg/day, at least 600 mg/day, at least 625 mg/day, at least 650 mg/day, at least 675 mg/day, at least 700 mg/day, at least 725 mg/day, at least 750 mg/day, at least 775 mg/day, at least 800 mg/day, at least 825 mg/day, at least 850 mg/day, at least 875 mg/day, at least 900 mg/day, at least 925 mg/day, at least 950 mg/day, at least 975 mg/day, at least 1000 mg/day, at least 1100 mg/day, at least 1200 mg/day, at least 1300 mg/day, at least 1400 mg/day, at least 1500 mg/day, at least 1600 mg/day, at least 1700 mg/day, at least 1800 mg/day, at least 1900 mg/day, at least 2000 mg/day, at least 2100 mg/day, at least 2200 mg/day, at least 2300 mg/day, at least 2400 mg/day, at least 2500 mg/day, at least 2600 mg/day, at least 2700 mg/day, at least 2800 mg/day, at least 2900 mg/day, at least 3000 mg/day, at least 3100 mg/day, at least 3200 mg/day, at least 3300 mg/day, at least 3400 mg/day, at least 3500 mg/day, at least 3600 mg/day, at least 3700 mg/day, at least 3800 mg/day, at least 3900 mg/day, or at least 4000 mg/day, and useful ranges can be selected between any of these values, e.g., from 20 mg/day to 4000 mg/day, 50 mg/day to 3000 mg/day, 75 mg/day to 2000 mg/day, 100 mg/day to 1000 mg/day, 200 mg/day to 2000 mg/day, 250 mg/day to 1500 mg/day, 100 mg/day to 500 mg/day, 250 mg/day to 2000 mg/day, 200 mg/day to 1000 mg/day, or an amount that is not less than 200 mg/day.
- In some embodiments, sialic acid can be administered during one or more of the stages of preconception, pregnancy/gestation and during lactation/postpartum. In some embodiments, sialic acid can be administered during a stage of pregnancy/gestation. In some embodiments, sialic acid can be administered during stage I of pregnancy/gestation (the first trimester), stage II of pregnancy/gestation (the second trimester), and/or stage III of pregnancy/gestation (third trimester). In some embodiments, sialic acid can be administered during preconception, stage I of pregnancy/gestation (the first trimester), stage II of pregnancy/gestation (the second trimester), stage III of pregnancy/gestation and/or during lactation/postpartum. In other embodiments, sialic acid can be administered during the first, second and/or third trimester and/or during lactation/postpartum. In other embodiments, sialic acid can be administered during the first, second, and/or third trimester. In some embodiments, sialic acid is administered can be administered during each stage of pregnancy. In some embodiments, sialic acid is administered continuously throughout each stage of pregnancy.
- In some embodiments, sialic acid can be administered during preconception and/or the first trimester. In some embodiments, sialic acid can be administered during the second trimester. In some embodiments, sialic acid can be administered during the third trimester. In some embodiments, sialic acid can be administered during lactation/postpartum. In some embodiments, sialic acid can be administered postpartum to the female during the first two years following birth.
- In some embodiments, a fetus is exposed to sialic acid by administration of sialic acid to a female pregnant with the fetus. In some embodiments, sialic acid supplementation can have benefits for the female even if the female is not breast feeding a child. In some embodiments, a sialic acid can be administered to the female and to a fetus or child. In some embodiments, a fetus is exposed to sialic acid by administration of sialic acid to the biological mother of the fetus. In some embodiments, a fetus is exposed to sialic acid by administration of sialic acid to a surrogate carrier of the fetus. In some embodiments, the fetus is exposed to sialic acid during the first, second and third trimesters of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the first and second trimesters of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the second and third trimesters of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the first and third trimesters of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the first trimester of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the second trimester of pregnancy. In some embodiments, the fetus is exposed to sialic acid during the third trimester of pregnancy.
- In some embodiments, a child is exposed to sialic acid by feeding the child an infant formula containing sialic acid. In some embodiments, a child is exposed to sialic acid by feeding the child breast milk containing sialic acid, wherein the breast milk is from a female receiving sialic acid supplementation as described herein. In some embodiments, a child is exposed to sialic acid by feeding the child breast milk containing sialic acid, wherein the breast milk is from the biological mother of the child receiving sialic acid supplementation as described herein. In some embodiments, a child is exposed to sialic acid by feeding the child breast milk containing sialic acid, wherein the breast milk is from the surrogate carrier of the child receiving sialic acid supplementation as described herein. In some embodiments, the child is exposed to sialic acid from birth to 5 years of age. In some embodiments, the child is exposed to sialic acid from birth to 4 years of age. In some embodiments, the child is exposed to sialic acid from birth to 3 years of age. In some embodiments, the child is exposed to sialic acid from birth to 2 years of age. In some embodiments, the child is exposed to sialic acid from birth to 1 year of age. In some embodiments, the child is exposed to sialic acid from 1 to 3 years of age. In some embodiments, the child is exposed to sialic acid from 1 to 2 years of age.
- In some embodiments, sialic acid can be provided on a daily basis during all or most of the period of time from birth to about 24 months of age. In some embodiments, sialic acid can be provided on less than a daily basis for a time period of less than two years, as long as desirable results are obtained. In some embodiments, sialic acid can be administered to the female beginning in the first trimester, continuing throughout gestation, and during about the first two years of lactation/breastfeeding following birth.
- In some embodiments, a dosage form comprises sialic acid and one or more excipients. In some embodiments, an excipient can be, for example, one or more additional nutritional supplements and/or maternal prenatal vitamins, including, but not limited to, one or more polyunsaturated fatty acids, calcium, folic acid, vitamin E, tocotrienols, vitamin D, magnesium, phosphorus, vitamin K, iron, vitamin B12, niacin, thiamine, riboflavin, biotin, vitamin B6, and isoflavones, zinc, pantothenic acid, medium chain triglycerides, copper, manganese, magnesium, vitamin A, choline, vitamin C, iodine, selenium, prebiotics, probiotics, beta-carotene, lutein, lycopene, alpha-carotene, zeaxanthin, beta-cryptoxanthin, gamma carotene, ginger, and tryptophan.
- In some embodiments, a composition or dosage form of the invention comprises sialic acid. In some embodiments, a composition or dosage form of the invention comprises sialic acid and infant formula. In some embodiments, a dosage form can comprise at least 0.1 mg, at least 1 mg, at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 85 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 105 mg, at least 110 mg, at least 115 mg, at least 120 mg, at least 125 mg, at least 130 mg, at least 135 mg, at least 140 mg, at least 145 mg, at least 150 mg, at least 200 mg, at least 250 mg, at least 300 mg, at least 350 mg, at least 400 mg, at least 450 mg, at least 500 mg, at least 550 mg, at least 600 mg, at least 650 mg, at least 700 mg, at least 750 mg, at least 800 mg, at least 850 mg, at least 900 mg, at least 950 mg, at least 1,000 mg, at least 1,100 mg, at least 1,200 mg, at least 1,300 mg, at least 1,400 mg, at least 1,500 mg, at least 1,600 mg, at least 1,700 mg, at least 1,800 mg, at least 1,900 mg, or at least 2,000 mg of sialic acid, and useful ranges can be selected between any of these values, e.g., from 0.1 mg to 2,000 mg of sialic acid, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg of sialic acid, 5 mg to 50 mg of sialic acid, 10 mg to 40 mg, or 25 mg to 1,000 mg of sialic acid.
- In some embodiments, a dosage form is administered to the female at least once a day, at least twice a day, at least three times a day, at least four times a day, at least five times a day, at least six times a day, at least seven times a day, at least eight times a day, at least nine times a day, or at least ten times a day. In some embodiments, a dosage form is administered to the female from once to ten times a day. In some embodiments, a dosage form is administered to the female from once to five times a day. In some embodiments, a dosage form is administered to the female from one to three times a day.
- In some embodiments, a female in preconception, pregnancy/gestation or lactation/postpartum receiving sialic acid supplementation can realize developmental benefits for a fetus and/or child. In some embodiments, the developmental benefit can be improved nervous system growth and/or development or growth of the brain. In some embodiments, the developmental benefit can be improved cognitive performance, earlier attainment of normal cognitive skills, improved motor skills, or earlier attainment of normal motor skills. In some embodiments, the developmental benefit can be a structural improvement in the brain that can include, but is not limited to, one of more of the following: increased expression and/or development of mature myelin, enhanced neurite extension, increased levels of myelin basic protein at earlier developmental timepoints, and enhanced development of the white matter of the brain. In some embodiments, an increased thickness of the myelin sheath and increased electrical conduction velocities can occur. In some embodiments, the white matter can be the corpus callosum, the lateral olfactory tract, the motor pyramids, the medullary pyramids, and/or the pyramids, but any or all white matter regions of the brain can be involved. In some embodiments, the developmental benefit can be enhanced development of the brain's hippocampus, which can include increased connectivity between brain cells, greater numbers of synapses, greater cell numbers, or longer cell survival times, but enhancement of these measures can be in any gray matter region of the brain (e.g., cerebral cortex, cerebellum, and all known nuclei of the brain). Methods for determining the developmental benefits are well known to persons of ordinary skill in the art (e.g., Calderon and Kim, J. Neurochem. 2004; 90:979-988; Donarum et al., J. Inherit. Metab. Dis. 2006; 29:143-156; Moriguchi and Salem, J. Neurochem. 2003; 87: 297-309) and described, for example, in the Examples.
- In some embodiments, a developmental benefit is increased neurite extension (e.g., hippocampal) in the brain of the child or fetus. In some embodiments, neurite extension with sialic acid supplementation is increased by at least 0.01%, at least 0.02%, at least 0.03%, at least 0.04%, at least 0.05%, at least 0.06%, at least 0.07%, at least 0.08%, at least 0.09%, at least 0.1%, at least 0.2%, at least 0.3%, at least 0.4%, at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 100% compared to neurite extension without sialic acid supplementation. Useful ranges can be selected between any of these values, e.g., neurite extension with sialic acid supplementation can be increased from 0.01% to 100%, 0.01% to 75%, 0.01% to 50%, 1% to 50%, 5% to 50%, 10% to 50%, 0.01% to 10%, 0.01% to 5%, 0.01% to 1%, 0.01% to 0.5%, 0.01% to 0.2% or 0.1% to 0.2%, compared to neurite extension without sialic acid supplementation. In some embodiments, increased neurite extension is measured by immunocytochemistry for the neuron-specific marker, Map2a. In some embodiments, increased neurite extension results from the administration of sialic acid to the female during preconception and/or pregnancy. In some embodiments, increased neurite extension results from the administration of sialic acid to the female during lactation. In some embodiments, increased neurite extension results from the administration of sialic acid to the female during pregnancy and not during lactation. In some embodiments, increased neurite extension results from the administration of sialic acid to the female during lactation and not during pregnancy.
- In some embodiments, a developmental benefit is increased levels of myelin basic protein (MBP) in the brain of the child or fetus. In some embodiments, MBP expression in the brain (e.g., whole brain, cerebellum, corpus callosum, frontal and/or rostral corpus callosum, middle corpus callosum, midline corpus callosum decussation, lateral olfactory tract, motor output pathways, sensory input pathways, motor pyramids, and/or medial lemniscus) with sialic acid supplementation is increased by at least 0.01%, at least 0.02%, at least 0.03%, at least 0.04%, at least 0.05%, at least 0.06%, at least 0.07%, at least 0.08%, at least 0.09%, at least 0.1%, at least 0.2%, at least 0.3%, at least 0.4%, at least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least 0.9%, at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 21%, at least 22%, at least 23%, at least 24%, at least 25%, at least 26%, at least 27%, at least 28%, at least 29%, at least 30%, at least 31%, at least 32%, at least 33%, at least 34%, at least 35%, at least 36%, at least 37%, at least 38%, at least 39%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 100% compared to MBP expression without sialic acid supplementation. Useful ranges can be selected between any of these values, e.g., MBP expression with sialic acid supplementation can be increased by 0.01% to 100%, 0.01% to 25%, 0.1% to 25%, 1% to 25%, 1% to 20%, 1% to 10%, 1% to 5%, or 5% to 20% compared to MBP expression without sialic acid supplementation. In some embodiments, MBP expression is measured by immunocytochemistry.
- In some embodiments, increased MBP expression results from the administration of sialic acid to the female during preconception and/or pregnancy. In some embodiments, increased MBP expression results from the administration of sialic acid to the female during lactation. In some embodiments, increased MBP expression results from the administration of sialic acid to the female during pregnancy and not during lactation. In some embodiments, increased MBP expression results from the administration of sialic acid to the female during lactation and not during pregnancy.
- In some embodiments, MBP expression with sialic acid supplementation is increased in the corpus callosum, rostral corpus callosum, midline corpus callosum, lateral olfactory tract and/or midline corpus callosum decussation compared to MBP expression without sialic acid supplementation. In some embodiments, MBP expression with sialic acid supplementation is increased in the corpus callosum, rostral corpus callosum, midline corpus callosum, lateral olfactory tract and/or midline corpus callosum decussation, and is not increased in the motor output pathways, sensory input pathways, motor pyramids and/or medial lemniscus compared to MBP expression without sialic acid supplementation. In some embodiments, MBP expression with sialic acid supplementation is increased in the corpus callosum, rostral corpus callosum, midline corpus callosum, lateral olfactory tract and/or midline corpus callosum decussation, and is not increased in the motor output pathways, sensory input pathways, motor pyramids and/or medial lemniscus compared to MBP expression without sialic acid supplementation, and the sialic acid is administered to the female during pregnancy. In some embodiments, MBP expression with sialic acid supplementation is increased in the corpus callosum, rostral corpus callosum, midline corpus callosum, lateral olfactory tract and/or midline corpus callosum decussation, and is not increased in the motor output pathways, sensory input pathways, motor pyramids and/or medial lemniscus compared to MBP expression without sialic acid supplementation, and the sialic acid is administered to the female during pregnancy and not during lactation.
- In some embodiments, MBP expression with sialic acid supplementation is increased in the cerebellum compared to MBP expression without sialic acid supplementation. In some embodiments, MBP expression with sialic acid supplementation is increased in the cerebellum compared to MBP expression without sialic acid supplementation, and the sialic acid is administered during lactation. In some embodiments, MBP expression with sialic acid supplementation is increased in the cerebellum compared to MBP expression without sialic acid supplementation, and the sialic acid is administered during lactation and not during pregnancy.
- In some embodiments, the sialic acid administered to a female at least in part crosses the blood brain barrier. In some embodiments, the sialic acid administered to a female is N-acetylneuraminic acid (NANA), which at least in part crosses the blood brain barrier. In some embodiments, the sialic acid administered to a female is NANA, which at least in part is converted into Neu5Gc in non-human animals. In some embodiments, the sialic acid administered to a female is NANA, which at least in part crosses the blood brain barrier and is at least in part converted into Neu5Gc in non-human animals.
- In some embodiments, the sialic acid administered to a female is present in the cerebrospinal fluid (CSF). In some embodiments, the sialic acid administered to a female is NANA, and the NANA is present at least in part in the CSF. In some embodiments, the sialic acid administered to a female is NANA, and the NANA is at least in part converted into Neu5Gc in non-human animals. In some embodiments, the sialic acid administered to a female is NANA, and the NANA is present at least in part in the CSF and is at least in part converted into Neu5Gc in non-human animals.
- In some embodiments, the invention relates to the use of any of the sialic acid compositions described herein in the preparation of a dosage form for any of the uses described herein.
- Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are not intended to be limiting.
- To determine the effects of supplementing maternal diets with sialic acid (n-acetylneuraminic acid; NANA) on the brain development of the offspring, forty (40) pregnant Long-Evans rats were placed on four (4) diets (10 dams per diet) that differed in their administration of sialic acid (Nacalai, San Diego, Calif.). All animals were started on the diets on the 4th day after being mated (gestational day 4).
- As shown in
FIG. 2 , control animals were placed on a base diet (“Base” or “None”) which contained no detectable amounts of NANA throughout gestation and lactation. Darns placed on the gestational diet (“Gest”) received NANA (200 milligrams (mg) per kilogram (kg) body weight per day (d)) only during gestation. These animals were then placed on a base diet after the offspring were born. Conversely, dams on the lactational diet (“fact”) were placed on the base diet during gestation but received NANA (200 mg/kg/d) through the diet during lactation. Dams receiving NANA (200 mg/kg/d) through the diet throughout gestation and lactation were known as the “G+L” group. -
FIG. 2 also shows how and when the offspring were used to determine the effects of the maternal diets on offspring development. After birth, the pups born to each diet group were crossfostered within their respective group to control for any differences in maternal care. The litters were then culled to 10 pups per dam to prevent nutritional differences caused by lack of access to the dam. The study was also designed to allow for the use of 5 pups at each endpoint (N=5) while keeping the litter size equal across all groups. Pups were taken at postnatal day 1 (p1) to determine potential differences between gestational supplementation and lactational supplementation of the maternal diet. Pups were taken at postnatal day 16 (p16) because they begin to access the mother's food directly at ˜p18, which would preclude any assessment of maternal transfer of NANA to the pups. Pups were also taken at p8 because it served as a midway timepoint and because the primary biomarker used cannot be detected until this day in rat development. -
FIGS. 3A and 3B show the maternal NANA supplementation protocol for experiments testing additional doses of NANA administered during gestation (FIG. 3A ) and lactation (FIG. 3B ). - As described in the following examples, three major endpoints were used in this study: myelin basic protein (MBP) expression in the developing whole brain, ex vivo neurite extension of neurons cultured from the hippocampus, and assessment of the thickness of MBP expression in the developing brain.
- MBP expression is a measure of brain development because it is a specific measure of the degree of mature myelination of the brain's circuitry. Myelin is the insulation between the “wires” of the brain and decreases electrical resistance in the brain's circuits much in the same way that insulation decreases electrical resistance in copper wiring. Decreased resistance allows for better signaling and subsequent developmental differentiation. Thus, the expression levels of mature myelin are associated with brains that are farther along in development.
- To determine the effects of maternal NANA supplementation on the brain development of offspring, MBP expression was measured by western blot analysis of whole brain lysates that were harvested from pups at
postnatal days FIG. 2 . As shown inFIG. 4A , the blots were probed with an antibody for MBP (lower panels; Millipore, Billerica, Mass. or Covance, Princeton, N.J.) that recognizes two distinct isoforms (18 and 21 kilodaltons [kDa] in molecular weight). The blots were also probed with an antibody for β-actin (upper panels; Cell Signaling Technologies, Beverly, Mass. or Millipore, Billerica, Mass.) that served as protein loading controls. - Quantitation of MBP expression, as shown in
FIG. 4B , was performed with densitometry of the bands in each lane, and each lane represented an individual animal. The graphs represent the average intensity of MBP expression normalized by the corresponding actin signal in relative fluorescence units (Normalized R.F.U.). One-way analysis of variance (ANOVA) detected a significant increase the expression of both 18 kDa MBP (F[3,32]=3.187; p=0.037; Power=0.681) and 21 kDa MBP (F[3,32]=4.270; p=0.012; Power=0.816) with NANA supplementation. In addition, Tukey's post hoc test detected that the lactational diet significantly increased the expression of both MBP isoforms (*, p<0.05) compared to the NANA-deficient diet in the overall analysis as well as atpostnatal day 8. - The hippocampus is a specific region of the brain that is essential for spatial learning and for moving short-term memories into long-term memory. Neurite extension in cultures of the hippocampus serves as a measure of brain cell growth, differentiation, and networking. Increases in these ex vivo measures are considered beneficial because it is believed that similar beneficial processes occur in vivo.
- To determine the effects of maternal NANA supplementation on the brain development of offspring, neurite extension was measured in hippocampal cultures made from p0 pups described in
FIG. 2 .FIG. 5A shows the measurements of offspring of dams exposed to a NANA-deficient diet during gestation.FIG. 5B shows the measurements of offspring of dams that were fed a NANA-supplemented (200 mg/kg/d) diet during gestation. After 6 days of incubation the cultures underwent immunocytochemistry for the neuron-specific marker, Map2a (Sigma, Ronkonkoma, NY; or Millipore, Billerica, Mass.). The number of cells in each culture was assessed by staining with 4′,6-diamidino-2-phenylindole (DAPI). - As shown in
FIG. 5C , quantitation of the percent area of Map2a staining per neuron was significantly greater in cultures derived from pups whose mothers had received NANA in their diets. The percent area of Map2a staining was determined by computerized counting of all Map2a positive pixels in each image (5 random fields for each of 9-10 cultures per group; 1 culture per animal). The number of Map2a positive pixels in an image was then divided by the total number of pixels in that same image. The resulting quotient was then multiplied by 100 to yield percent (%) area. The percent area was then divided by the total number of cells in the image in order to normalize for cell number. A two-tailed, unpaired students t-test was used to compare the two groups, and the test detected a significant difference between the supplemented group and the control group (**, p<0.01). Thus, maternal exposure to NANA significantly increased neurite extension in hippocampal cultures of the offspring. - To further assess the dose-response effects of maternal NANA supplementation during gestation on the brain development of offspring, neurite extension was measured in hippocampal cultures made from pups described in
FIG. 3A .FIG. 6A shows representative hippocampal cultures derived from offspring of dams having a NANA-deficient diet during gestation (“no NANA”) or a NANA-supplemented (25 mg/kg/d NANA, 50 mg/kg/d NANA, 100 mg/kg/d NANA, and 200 mg/kg/d NANA) diet during gestation. After 6 days of incubation, the cultures underwent immunocytochemistry for the neuron-specific marker, Map2a (Sigma, Ronkonkoma, N.Y.; or Millipore, Billerica, Mass.). The number of cells in each culture was assessed by staining with 4′,6-diamidino-2-phenylindole (DAPI). - The percent area of Map2a staining per neuron was quantitated as described in Example 3. As shown in
FIG. 6B , the percent area of Map2a staining per neuron was significantly greater in cultures derived from pups whose mothers had received NANA in their diets (**, p<0.01; ***, p<0.001). Thus, maternal exposure to NANA significantly increased neurite extension in hippocampal cultures of the offspring. - Increased thickness and maturity of the myelin sheath is associated with faster conduction velocities and more advanced development and differentiation of white matter (myelinated brain areas). In particular, the corpus callosum (CC) is the major tract for communication between the two cerebral hemispheres that control executive function and learning Also, the lateral olfactory tract (LOT) is particularly important in rodents because they rely largely on their olfactory system for orientation and food-guided behavior in their normal environments. The LOT carries information from the primary olfaction centers of the olfactory bulbs to higher processing centers in the cerebrum and hippocampus. The CC and LOT were measured in the following experiments because of their size and because of their importance in brain function and in the animals' abilities to sense their environments
- To determine the effects of maternal NANA supplementation on the brain development of offspring, assessment of the CC and LOT was performed by taking thin slices of the p16 pup brain described in
FIG. 2 , staining the slices with MBP irnmunohistochemistry, and measuring the areas of interest with confocal laser microscopy. As shown inFIG. 7A , the thickness of MBP expression in the CC was measured at the cingulum (dashed line) in rostral (less developed) and midline (more developed) areas of the brain (scale bar=1 millimeter). The locations of the LOT and regions associated with the anterior commissure (AC) are also illustrated inFIG. 7A . -
FIG. 7B shows maternal NANA supplementation during gestation (Gest), lactation (Lact), or gestation plus lactation (G+L) (as described inFIG. 2 ) resulted in significant increases [multivariate ANOVA; F[3,86]=8.455; p<0.001] to the thickness of MBP expression in the CC in the offspring (p<0.05; **, p<0.01; and ***, p<0.001).FIG. 7C shows maternal NANA supplementation also resulted in significant increases to the maximal thickness of MBP expression in the LOT which were similar to those detected in the CC. Furthermore, these findings were consistent with the Western blot findings described in Example 2. - To further assess the effects of maternal NANA supplementation during gestation on the brain development of offspring, assessment of the corpus callosum (CC) and lateral olfactory tract (LOT) was performed by taking thin slices of the p16 pup brain (GestDR p16) described in
FIG. 3A , staining the slices with MBP immunohistochemistry, and quantitating the areas of interest with confocal laser microscopy as described in Example 2. Maternal supplementation with NANA at doses of 25 mg/kg/d, 50 mg/kg/d, 100 mg/kg/d and 200 mg/kg/d was tested. -
FIG. 8A shows maternal NANA supplementation during gestation resulted in significant increases to the thickness of MBP expression in the frontal CC in the offspring (***, p<0.001).FIG. 8B shows maternal NANA supplementation did not appear to change the thickness of MBP expression in the middle CC.FIG. 8C shows maternal NANA supplementation resulted in significant increases to the thickness of MBP expression in the LOT (*, p<0.05; ***, p<0.001).FIG. 8D shows maternal NANA supplementation did not appear to change the thickness of MBP expression in the midline CC decussation. - The white matter of the spinal cord contains tracts of fibers that are ascending (sensory) or descending (motor). The ascending tracts convey sensory information from cutaneous receptors, proprioceptors (muscle and joint senses) and visceral receptors. The medial lemniscus is a pathway that carries such sensory information from the gracile and cuneate nuclei to the thalamus. There are two major descending tracts: the corticospinal, or pyramidal tract, and the extrapyramidal tract. In general, these tracts are involved in the control of the musculature of the body.
- To further assess the effects of maternal NANA supplementation during gestation on the brain development of offspring, assessment of the motor pyramids and medial lemniscus was performed by taking thin slices of the p16 pup brain described in
FIG. 3A , staining the slices with MBP immunohistochemistry, and quantitating the areas of interest with confocal laser microscopy as described in Example 2. Maternal supplementation with NANA at doses of 25 mg/kg/d, 50 mg/kg/d, 100 mg/kg/d and 200 mg/kg/d was tested. -
FIG. 9A shows maternal NANA supplementation during gestation resulted in significant increases to the thickness of MBP expression in the motor pyramids in the offspring (*, p<0.05; **, p<0.01; ***, p<0.001).FIG. 9B shows maternal NANA supplementation resulted in significant increases to the thickness of MBP expression in the medial lemniscus (*, p<0.05; **, p<0.01). - To further assess the effects of maternal NANA supplementation during lactation on the brain development of offspring, assessment of the corpus callosum (CC) and lateral olfactory tract (LOT) was performed by taking thin slices of the p16 pup brain (LacDR p16) described in
FIG. 3B , staining the slices with MBP immunohistochemistry, and quantitating the areas of interest with confocal laser microscopy as described in Example 2. Maternal supplementation with NANA at doses of 25 mg/kg/d, 50 mg/kg/d, 100 mg/kg/d and 200 mg/kg/d was tested. -
FIG. 10A shows maternal NANA supplementation during lactation resulted in significant increases to the thickness of MBP expression in the rostral CC in the offspring (**, p<0.01; ***, p<0.001).FIG. 10B shows maternal NANA supplementation during lactation resulted in significant increases to the thickness of MBP expression in the midline CC in the offspring (**, p<0.01; ***, p<0.001).FIG. 10C shows maternal NANA supplementation during lactation resulted in significant increases to the thickness of MBP expression in the LOT in the offspring (***, p<0.001).FIG. 10D shows maternal NANA supplementation during lactation resulted in significant increases to the thickness of MBP expression in the midline CC decussation in the offspring (*, p<0.05; ***, p<0.001). - Example 9
- Maternal Feeding of Varying NANA Doses During Lactation and MBP Expression in Motor Output and Sensory Input Pathways:
- To further assess the effects of maternal NANA supplementation during lactation on the brain development of offspring, assessment of the motor pyramids and medial lemniscus was performed by taking thin slices of the p16 pup brain (LacDR p16) described in
FIG. 3B , staining the slices with MBP immunohistochemistry, and quantitating the areas of interest with confocal laser microscopy as described in Example 2. Maternal supplementation with NANA at doses of 25 mg/kg/d, 50 mg/kg/d, 100 mg/kg/d and 200 mg/kg/d was tested. -
FIG. 11A shows maternal NANA supplementation during lactation resulted in a significant increase to the thickness of MBP expression in the motor pyramids following maternal supplementation with NANA at a dose of 50 mg/kg/d in the offspring (*, p=0.022) and no significant changes to the thickness of MBP expression in the motor pyramids following maternal supplementation with NANA at the other doses tested.FIG. 11B shows maternal NANA supplementation during lactation resulted in no significant changes to the thickness of MBP expression in the medial lemniscus in the offspring. - To further assess the effects of maternal NANA supplementation during lactation on the brain development of offspring, MEW expression was measured by western blot analysis of cerebellum that was harvested from pups at
postnatal days FIG. 3B . As described in Example 2, the blots were probed with an antibody for MBP as described in Example 2 that recognizes the 18 kilodalton form (18 kD MBP) and 21 kilodalton form (21 kD MBP) and an antibody for β-actin as a protein loading control. Quantitation of MBP expression performed with densitometry of the bands in each lane, and each lane represented an individual animal as described in Example 2. - The graphs in
FIGS. 12A and 12B represent the average intensity of MBP expression normalized by the corresponding actin signal in relative fluorescence units (Normalized R.F.U.). One-way analysis of variance (ANOVA) detected a significant increase the expression of both 18 kDa MBP and 21 kDa MBP with NANA supplementation during lactation at certain doses tested (p<0.001). - Analysis of the combined expression intensities of 18 kDa MBP and 21 kDa MBP showed a significant increase in total MBP following NANA supplementation during lactation at NANA doses of 25 mg/kg/d (p<0.01), 100 mg/kg/d (p<0.05), and 200 mg/kg/d (p<0.01).
- To assess whether NANA is bioavailable to the brain in its native form or whether NANA is processed on its way across the blood-brain barrier, the levels of NANA and one of its potential metabolites were measured in rat cerebrospinal fluid (CSF). The animals' diets were first cleared of NANA by placing them on NANA-flee diets for one week. The animals were then given a single, oral dose of NANA (200 mg/kg), and the CSF of each animal was sampled at 0, 0.25, 1, 2, 4, and 6 hours after dosing. The concentrations of NANA and Neu5Gc in the CSF were then assessed by high-pressure liquid chromatography coupled with fluorescence detection methods and quantitation standards.
-
FIG. 13 illustrates the changes in the concentrations of NANA and Neu5Gc in the CSF after oral NANA dosing. AsFIG. 13A shows, a peak of native NANA was detectable above baseline 15 minutes after dosing. This NANA peak then decayed relatively rapidly and returned to baseline values by 1 hour after oral NANA dosing. These data suggest that native NANA crossed the blood-brain barrier as a result of the exogenous dosing. NANA was then either absorbed into the brain tissue itself, processed into metabolites such as Neu5Gc or ManNAc, or both. Indeed, asFIG. 13B shows, at least some of the NANA was likely being converted to Neu5Gc. The Neu5Gc concentrations did not increase above baseline until 1 hour after oral dosing, and this increase was noticeably after the NANA peak observed at 15 minutes after dosing. The Neu5Gc concentrations were then sustained throughout the rest of the sampling period at levels that were approximately 4% of the peak NANA concentration. Thus, exogenous NANA is bioavailable to the brain, but it is also processed to some extent. It should be noted here that, unlike all other mammals, humans do not possess a functional enzyme for converting NANA to Neu5Gc, so the data would likely be different in human CSF. - The foregoing description of the invention has been presented for purposes of illustration and description. Furthermore, the description is not intended to limit the invention to the form disclosed herein.
- All of the various aspects, embodiments, and options described herein can be combined in any and all variations,
- All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
Claims (22)
1. A method for providing sialic acid to a female, comprising administering sialic acid to the female during at least one of the stages of preconception, pregnancy and lactation,
wherein the sialic acid provides a developmental benefit to a fetus or child of the female.
2. The method of claim 1 , wherein the sialic acid is a free sialic acid.
3. The method of claim 1 , wherein the sialic acid is selected from the group consisting of: oligosaccharide conjugates, lipid conjugates, protein conjugates, and combinations thereof,
4. The method of claim 1 , wherein the sialic acid is selected from the group consisting of: 3′sialyllactose, gangliosides, casein glycomacropeptide, and combinations thereof.
5. The method of claim 1 , wherein the sialic acid is a sialic acid precursor that is metabolized into sialic acid.
6. The method of claim 5 , wherein the sialic acid precursor is selected from the group consisting of: N-acetylmannosamine, N-propanoylmannosamine, 2-keto-3-deoxynononic acid, N-glycolylneuraminic acid, the core sialic acid neuraminic acid molecule, and combinations thereof.
7. The method of claim 1 , wherein the sialic acid is administered during pregnancy and lactation.
8. The method of claim 1 , wherein the sialic acid is administered during preconception, pregnancy and lactation.
9. The method of claim 1 , wherein the sialic acid is administered to the female during the first two years following birth of a child by the female.
10. The method of claim 1 , wherein the developmental benefit is improved development of the nervous system and/or brain.
11. The method of claim 1 , wherein the developmental benefit is a neurological improvement of the brain.
12. The method of claim 1 , wherein the developmental benefit is selected from the group consisting of: increased expression and/or development of mature myelin, enhanced neurite extension, increased levels of myelin basic protein, enhanced development the white matter of the brain, and combinations thereof.
13. The method of claim 1 , wherein the developmental benefit is in the gray matter of the brain.
14. The method of claim 1 , wherein the sialic acid is administered in a dosage form.
15. The method of claim 14 , wherein the dosage form is selected from the group consisting of: nutritional supplement, food, pharmaceutical formulation, beverage, and combinations thereof.
16. The method of claim 14 , wherein the dosage form contains sialic acid at an amount of 0.01% to 10% by weight of the dosage form.
17. The method of claim 14 , wherein the dosage form contains sialic acid at an amount of 10% to 90% by weight of the dosage form.
18. The method of claim 1 , wherein the sialic acid is administered at an amount of 5 mg/kg/day to 200 mg/kg/day of the female's body weight.
19. The method of claim 18 , wherein the sialic acid is administered at an amount of 25 mg/kg/day to 100 mg/kg/day of the female's body weight.
20. The method of claim 1 , wherein the sialic acid is administered at an amount of 20 mg/day to 4000 mg/day.
21. The method of claim 20 , wherein the sialic acid is administered at an amount of 200 mg/day to 2000 mg/day.
22. The method of claim 1 , further comprising administering to the female one or more polyunsaturated fatty acids, calcium, folic acid, vitamin B, tocotrienols, vitamin D, magnesium, phosphorus, vitamin K, iron, vitamin B12, niacin, thiamine, riboflavin, biotin, vitamin B6, and isoflavones, zinc, pantothenic acid, medium chain triglycerides, copper, manganese, magnesium, vitamin A, choline, vitamin C, iodine, selenium, prebiotics, probiotics, beta-carotene, lutein, lycopene, alpha-carotene, zeaxanthin, beta-cryptoxanthin, gamma carotene, ginger, and tryptophan.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/084,986 US20140080767A1 (en) | 2010-03-12 | 2013-11-20 | Maternal sialic acid supplementation |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31363010P | 2010-03-12 | 2010-03-12 | |
PCT/US2011/028068 WO2011112913A1 (en) | 2010-03-12 | 2011-03-11 | Maternal sialic acid supplementation |
US201213634467A | 2012-11-20 | 2012-11-20 | |
US14/084,986 US20140080767A1 (en) | 2010-03-12 | 2013-11-20 | Maternal sialic acid supplementation |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/634,467 Continuation US8703716B2 (en) | 2010-03-12 | 2011-03-11 | Maternal sialic acid supplementation |
PCT/US2011/028068 Continuation WO2011112913A1 (en) | 2010-03-12 | 2011-03-11 | Maternal sialic acid supplementation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140080767A1 true US20140080767A1 (en) | 2014-03-20 |
Family
ID=44563861
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/634,467 Active 2031-03-30 US8703716B2 (en) | 2010-03-12 | 2011-03-11 | Maternal sialic acid supplementation |
US14/084,986 Abandoned US20140080767A1 (en) | 2010-03-12 | 2013-11-20 | Maternal sialic acid supplementation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/634,467 Active 2031-03-30 US8703716B2 (en) | 2010-03-12 | 2011-03-11 | Maternal sialic acid supplementation |
Country Status (18)
Country | Link |
---|---|
US (2) | US8703716B2 (en) |
EP (1) | EP2544539B1 (en) |
JP (1) | JP6028264B2 (en) |
KR (1) | KR101910203B1 (en) |
CN (2) | CN102946728B (en) |
AU (1) | AU2011224220C1 (en) |
BR (1) | BR112012023004A2 (en) |
CA (1) | CA2792112C (en) |
EA (1) | EA025117B1 (en) |
ES (1) | ES2540994T3 (en) |
HK (1) | HK1209000A1 (en) |
MX (1) | MX2012010533A (en) |
MY (1) | MY160679A (en) |
NZ (1) | NZ602370A (en) |
PL (1) | PL2544539T3 (en) |
SG (2) | SG183978A1 (en) |
WO (1) | WO2011112913A1 (en) |
ZA (1) | ZA201206801B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9993457B2 (en) | 2014-11-25 | 2018-06-12 | Abbott Laboratories | Method of improving visual processing, visual acuity, or both by administering compositions comprising RRR-alpha-tocopherol and carotenoid to infants |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017004118B1 (en) | 2014-09-30 | 2022-04-12 | Kimberly-Clark Worldwide, Inc | Creped paper web, multi-layer creped paper product, and, method of making a prebiotic creped paper web |
WO2016053308A1 (en) | 2014-09-30 | 2016-04-07 | Kimberly-Clark Worldwide, Inc. | Synergistic prebiotic composition |
WO2016145628A1 (en) * | 2015-03-18 | 2016-09-22 | Nestec S.A. | Composition comprising siallyllactose for use in enhancing learning skills and memory function |
CN104757460A (en) * | 2015-04-10 | 2015-07-08 | 广西大学 | Phaseolus anagularis-pumpkin-carrot health care nutrition powder and making method thereof |
CN104738647A (en) * | 2015-04-10 | 2015-07-01 | 广西大学 | White hyacinth bean, potato and pineapple health nutritional powder and preparation method thereof |
CN104856059A (en) * | 2015-06-03 | 2015-08-26 | 广西大学 | Weight-losing health nutrition powder |
CN104996986A (en) * | 2015-07-10 | 2015-10-28 | 武汉中科光谷绿色生物技术有限公司 | Food application of N-acetylneuraminic acid fermented from E. coli |
MX2018007124A (en) | 2015-12-15 | 2018-09-07 | Nestec Sa | Mixture of hmos. |
SG11201803023UA (en) * | 2016-03-30 | 2018-05-30 | Nestec Sa | Compositions comprising minerals and their use |
RU2019105567A (en) | 2016-07-28 | 2020-08-28 | Фонтерра Ко-Оперэйтив Груп Лимитед | DAIRY PRODUCT AND METHOD |
JP6762027B2 (en) * | 2016-08-25 | 2020-09-30 | 株式会社雅嘉貿易 | Manufacturing method of cyanooligosaccharide and its use |
CN106723051A (en) * | 2017-01-20 | 2017-05-31 | 西宝生物科技(上海)股份有限公司 | A kind of brain healthy composition and preparation method thereof |
EP3847457A4 (en) * | 2018-09-04 | 2022-08-31 | Milkstrip Ltd. | A method for testing body fluids |
WO2020128876A1 (en) | 2018-12-19 | 2020-06-25 | Presinus Pharmaceuticals Private Limited | Composition comprising iodine; selenium, vitamin d3 and lycopene for the prevention and treatment of hypothyroidism |
SG10201900604TA (en) * | 2019-01-23 | 2020-08-28 | Agency For Science Technology And Research Astarstar | Pre-natal beta-cryptoxanthin benefits children |
WO2020259540A1 (en) * | 2019-06-25 | 2020-12-30 | 嘉必优生物技术(武汉)股份有限公司 | Use of sialic acid compounds in the preparation of drugs or nutritional additives or food products for treating brain degeneration |
CN113424964B (en) * | 2021-06-17 | 2022-05-27 | 汤臣倍健股份有限公司 | Composition and its use in preparing health food or food for regulating human milk nutrition and immunity components |
WO2023049853A1 (en) * | 2021-09-23 | 2023-03-30 | The Regents Of The University Of California | Promoting myelination by n-acetylglucosamine and modulation of n-glycan branching |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4044630B2 (en) * | 1996-05-16 | 2008-02-06 | 雪印乳業株式会社 | Brain function improver |
JP2997419B2 (en) * | 1996-05-31 | 2000-01-11 | 雪印乳業株式会社 | Brain ganglioside content decrease inhibitor |
WO2003017945A2 (en) * | 2001-08-24 | 2003-03-06 | Martek Biosciences Boulder Corporation | Products containing highly unsaturated fatty acids for use by women and their children during stages of preconception, pregnancy and lactation/post-partum |
US7951410B2 (en) | 2003-04-14 | 2011-05-31 | Mead Johnson Nutrition Company | Enteral compositions containing caseinoglycomacropeptide having an enhanced concentration of sialic acid |
US7867541B2 (en) | 2003-04-14 | 2011-01-11 | Mead Johnson Nutrition Company | Compositions and methods of formulation for enteral formulas containing sialic acid |
CA2530170A1 (en) | 2003-06-24 | 2005-01-06 | University Of Kansas Medical Center | Infant formula |
CN1701789A (en) * | 2005-05-13 | 2005-11-30 | 韩孝清 | Nutrition replenisher containing sialic acid and its derivative |
CA2556343A1 (en) * | 2005-09-01 | 2007-03-01 | Purepharm Inc. | Synthetic nutritional formulations |
US20080003330A1 (en) * | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Infant formulas for early brain development |
WO2008150477A2 (en) * | 2007-05-31 | 2008-12-11 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | N-acetyl mannosamine as a therapeutic agent |
CA2702570A1 (en) | 2007-10-19 | 2009-04-23 | Christopher Paul Mcjarrow | Methods of maintaining or increasing growth or cognitive development |
EP2096115A1 (en) | 2008-02-26 | 2009-09-02 | Nestec S.A. | Oligosaccharide ingredient |
EP2110027A1 (en) | 2008-04-01 | 2009-10-21 | Nestec S.A. | Long-chain polyunsaturated fatty acids (LC-PUFA) in maternal nutrition during pregnancy and lactation |
EP2116139A1 (en) * | 2008-05-08 | 2009-11-11 | Nestec S.A. | Sialic acid to support brain health in the elderly |
WO2009144977A1 (en) * | 2008-05-28 | 2009-12-03 | ジャパン・フード&リカー・アライアンス株式会社 | Oral composition for hair growth |
US20110053889A1 (en) | 2008-09-02 | 2011-03-03 | Joanne Szabo | Prenatal and postnatal screening and treatment of critical monosaccharide deficiencies for neurologic and immunologic function |
EP2183984B1 (en) | 2008-11-10 | 2011-12-28 | Nestec S.A. | Sialic acid producing bacteria |
-
2011
- 2011-03-11 JP JP2012557273A patent/JP6028264B2/en not_active Expired - Fee Related
- 2011-03-11 AU AU2011224220A patent/AU2011224220C1/en not_active Ceased
- 2011-03-11 EA EA201201281A patent/EA025117B1/en not_active IP Right Cessation
- 2011-03-11 ES ES11754146.6T patent/ES2540994T3/en active Active
- 2011-03-11 CN CN201180013637.9A patent/CN102946728B/en active Active
- 2011-03-11 NZ NZ602370A patent/NZ602370A/en not_active IP Right Cessation
- 2011-03-11 WO PCT/US2011/028068 patent/WO2011112913A1/en active Application Filing
- 2011-03-11 CN CN201510091530.6A patent/CN104687046A/en active Pending
- 2011-03-11 SG SG2012066809A patent/SG183978A1/en unknown
- 2011-03-11 EP EP11754146.6A patent/EP2544539B1/en not_active Revoked
- 2011-03-11 PL PL11754146T patent/PL2544539T3/en unknown
- 2011-03-11 BR BR112012023004A patent/BR112012023004A2/en not_active Application Discontinuation
- 2011-03-11 MY MYPI2012700622A patent/MY160679A/en unknown
- 2011-03-11 KR KR1020127026605A patent/KR101910203B1/en active IP Right Grant
- 2011-03-11 SG SG10201500853TA patent/SG10201500853TA/en unknown
- 2011-03-11 US US13/634,467 patent/US8703716B2/en active Active
- 2011-03-11 CA CA2792112A patent/CA2792112C/en active Active
- 2011-03-11 MX MX2012010533A patent/MX2012010533A/en unknown
-
2012
- 2012-09-11 ZA ZA2012/06801A patent/ZA201206801B/en unknown
-
2013
- 2013-11-20 US US14/084,986 patent/US20140080767A1/en not_active Abandoned
-
2015
- 2015-10-08 HK HK15109860.1A patent/HK1209000A1/en unknown
Non-Patent Citations (1)
Title |
---|
Hedlund et al ("N-Glycolylneuraminic Acid Deficiency in Mice: Implications forHuman Biology and Evolution" (2007) Mol Cell Bio 127(12) 4340-4346) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9993457B2 (en) | 2014-11-25 | 2018-06-12 | Abbott Laboratories | Method of improving visual processing, visual acuity, or both by administering compositions comprising RRR-alpha-tocopherol and carotenoid to infants |
US10245250B2 (en) | 2014-11-25 | 2019-04-02 | Abbott Laboratories | Method of improving visual processing, visual acuity, or both by administering compositions comprising RRR-alpha-tocopherol to infants |
Also Published As
Publication number | Publication date |
---|---|
MY160679A (en) | 2017-03-15 |
CN102946728A (en) | 2013-02-27 |
EP2544539B1 (en) | 2015-04-29 |
CN102946728B (en) | 2015-09-23 |
AU2011224220A1 (en) | 2012-10-04 |
NZ602370A (en) | 2014-11-28 |
AU2011224220C1 (en) | 2016-03-10 |
WO2011112913A1 (en) | 2011-09-15 |
KR20130008581A (en) | 2013-01-22 |
ZA201206801B (en) | 2014-03-26 |
CN104687046A (en) | 2015-06-10 |
JP2013522234A (en) | 2013-06-13 |
CA2792112C (en) | 2018-09-04 |
HK1209000A1 (en) | 2016-03-24 |
EA201201281A1 (en) | 2013-10-30 |
EP2544539A4 (en) | 2013-07-31 |
CA2792112A1 (en) | 2011-09-15 |
SG10201500853TA (en) | 2015-04-29 |
EA025117B1 (en) | 2016-11-30 |
US8703716B2 (en) | 2014-04-22 |
US20130137643A1 (en) | 2013-05-30 |
MX2012010533A (en) | 2013-02-11 |
EP2544539A1 (en) | 2013-01-16 |
SG183978A1 (en) | 2012-10-30 |
JP6028264B2 (en) | 2016-11-16 |
PL2544539T3 (en) | 2015-10-30 |
BR112012023004A2 (en) | 2015-09-15 |
ES2540994T3 (en) | 2015-07-15 |
AU2011224220B2 (en) | 2014-10-23 |
KR101910203B1 (en) | 2018-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8703716B2 (en) | Maternal sialic acid supplementation | |
Koletzko et al. | Growth, development and differentiation: a functional food science approach | |
TW201438719A (en) | Human milk oligosaccharides to ameliorate symptoms of stress | |
TW201429410A (en) | Neuroprotective dietary oligosaccharides | |
MX2011003433A (en) | Nutritional composition to promote healthy development and growth. | |
CN103054048A (en) | Infant nutritional compositions for preventing obesity | |
CN101384184A (en) | Infant nutritional compositions for preventing obesity | |
JP2009542226A (en) | Enhanced infant formula | |
TW201438720A (en) | Dietary oligosaccharides to enhance learning and memory | |
EP3574771A1 (en) | Infant formula with special lipid architecture for promoting healthy growth | |
US20160021921A1 (en) | Preterm infant nutritional compositions containing beta-hydroxy-beta-methylbutyric acid | |
US20240000122A1 (en) | Compositions comprising human milk oligosaccharides for use in a subject to support night sleep duration | |
US20140377404A1 (en) | Use of specific carbohydrate systems during pregnancy for effecting the offspring | |
EP2614725A1 (en) | Use of specific carbohydrate systems during pregnancy for improving lean body mass development and formation and reducing adverse health effects later in life in offspring | |
US20160029679A1 (en) | Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women | |
EP2614724A1 (en) | Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring | |
Gebauer et al. | What is new in infant nutrition? | |
US20240100075A1 (en) | Synthetic Compositions Comprising LNFP III and LSTa | |
US20240197772A1 (en) | COMPOSITIONS COMPRISING ONE OR MORE HMO'S WITH A CORE OF LacNAc-Lac | |
US20230013403A1 (en) | Compositions comprising human milk oligosaccharides for use in a subject to support language development | |
CA3183203A1 (en) | Mct formulations for improving cognitive functions and methods of making and using such formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DSM IP ASSETS B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZIMMER, JOHN PAUL;BUTT, CHRISTOPHER MICHAEL;REEL/FRAME:032290/0001 Effective date: 20121108 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |